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Lymphomas are a complex group of cancers arising from mature lymphoid cells. Despite 
advances in the treatment and management of this disease, it remains a health challenge as 
response to treatment and survival outcomes differ in various lymphoma subtypes. The exact 
causes driving lymphomagenesis remain unknown, and although several risk factors have been 
identified, the complexity of this disorder indicates that different molecular mechanisms drive 
the disease. One primary event evident in this disease is the presence of epigenetic alterations.  
Epigenetic alterations could arise due to changes in the pattern of deoxyribonucleic acid (DNA) 
methylation or histone modifications. Enhancer of zeste homolog 2 (EZH2) modifies histone 
and mediates gene silencing by selectively catalyzing lysine 27 trimethylation on histone H3 
(H3K27me3). Consequently, genes responsible for tumor suppression and differentiation are 
repressed, cells undergo uncontrolled proliferation, and this leads to tumor formation. EZH2 
has been mentioned to be a driver oncogene that plays an important role in tumor initiation and 
progression, especially when overexpressed or when gain-of function mutations occur in this 
gene. These hotspot gain-of-function mutations (Tyr646, Ala682 and Ala692) that result in 
increased EZH2 activity, are associated with increased H3K27me3 in several cancer types 
including lymphomas. Therefore, EZH2 inhibition could be an alternative strategy for 
lymphoma therapy.  
We treated aggressive B-cell lymphoma cell lines with 3-Deazaneplanocin A (DZNep), an 
epigenetic drug that inhibits EZH2 indirectly and promotes apoptosis in various tumor entities 
including lymphomas. We aimed to investigate the apoptotic efficacy of DZNep in these 
lymphoma cell lines, to understand the mechanisms of resistance to DZNep and to determine 
predictive biomarkers that could be of importance for EZH2 inhibition with DZNep. 
Using a combination of molecular and cell biological techniques such as flow cytometry, 
Western blot, Sanger sequencing, fluorescence in situ hybridization (FISH) and real-time 
reverse transcriptase polymerase chain reaction (RT-PCR), we showed that DZNep possesses 
a strong apoptotic and anti-proliferative effect on B-cell lymphoma cell lines. This effect was 
independent of the lymphoma type, the presence of EZH2 gain-of-function mutations or the 
presence of known prognostic lymphoma biomarkers such as translocations of MYC, BCL2 and 
BCL6. To investigate the molecular mechanism behind resistance to DZNep, we generated a 
DZNep-resistant clone from a B-cell lymphoma cell line that was initially sensitive to DZNep. 
This clone was used as a model to elucidate this mechanism. Upon molecular characterization, 
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comparison of this clone with the parent cell line of origin revealed differences in the karyotype, 
copy number alterations, proliferation rate and response to DZNep. Clonality studies of the 
rearranged immunoglobulin genes however, demonstrated that the resistant clone and the parent 
cell line were clonally identical.  
Whole exome sequencing performed on this clone in relation to its corresponding control 
revealed among others, a genomic amplification of the AHCY gene - a direct target of DZNep. 
Methods such as copy number variation assays, FISH, gene expression assays and 
immunohistochemistry were used to validate this massive AHCY gain at the DNA, 
chromosomal, transcriptional and translational levels respectively. Functional validation of 
AHCY showed that in a DZNep-sensitive osteosarcoma cell line, AHCY overexpression was 
associated with resistance to DZNep. Unfortunately, reproduction of AHCY function in 
lymphoma cell lines was not successful due to technical reasons. Further evaluation of the 
whole exome sequencing data from DZNep-resistant cell lines demonstrated in one of the cell 
lines, a mutation in the AHCY gene. This mutation was predicted from online databases to have 
a likely damaging effect on the protein.  
This study thus presents alterations in the AHCY gene as a potential mechanism of resistance to 
DZNep. It also reveals that molecular mechanisms of acquired resistance are quite distinct from 
those of intrinsic resistance to DZNep, which themselves, may further differ from one DZNep-
resistant lymphoma entity to the next. AHCY could therefore, be a promising biomarker to 












Lymphome repräsentieren eine heterogene Gruppe von hämatologischen Neoplasien, die aus 
reifen lymphatischen Zellen hervorgehen. Trotz der Fortschritte bei der Diagnostik und der 
Behandlung dieser Krankheit bleiben Lymphome eine therapeutische Herausforderung, da der 
Therapieerfolg bei den verschiedenen Lymphom-Subtypen sehr unterschiedlich ist. Die 
genauen Ursachen für die Pathogenese der Lymphome sind weitgehend unbekannt, und obwohl 
verschiedene Risikofaktoren identifiziert wurden, kann davon ausgegangen werden, dass 
verschiedene molekulare Mechanismen hierfür verantwortlich sind. Ein wichtiger 
Mechanismus scheinen jedoch epigenetische Veränderungen zu sein. 
Epigenetischen Modifikationen können Änderungen im Methylierungsmuster innerhalb der 
Desoxyribonukleinsäure (DNA) oder Histon umfassen. Enhancer of zeste homolog 2 (EZH2) 
modifiziert Histone und katalysiert die Gen-Stummschaltung durch selektive Trimethylierung 
von Lysin an Position 27 von Histon H3 (H3K27me3). Als Folge dessen, werden 
Tumorsuppressor- und Differenzierungsgene unterdrückt, so dass die Zellen einer 
unkontrollierten Zellproliferation unterliegen, welche letztlich zur Tumorbildung führt. Als 
Onkogen spielt EZH2 - insbesondere wenn EZH2 überexprimiert wird oder wenn in diesem 
Gen funktionssteigernde Mutationen auftreten - eine wichtige Rolle bei der Tumorinitiierung 
und -progression. So führen EZH2 Mutationen an Position Tyr646, Ala682 oder Ala692 zu 
einer erhöhten EZH2-Aktivität und somit zu einer Erhöhung der Trimethylierung von H3K27 
bei verschiedenen Krebsarten, einschließlich Lymphomen. Deshalb könnte die Hemmung der 
EZH2-Aktivität eine alternative Strategie für eine Lymphomtherapie darstellen. 
3-Deazaneplanocin A (DZNep) ist ein indirekter EZH2-Inhibitor, der bei verschiedenen 
Tumorentitäten, unter anderen auch aggressiven Lymphomtypen, Apoptose auslöst. Wir haben 
es uns zum Ziel gesetzt die apoptotische Wirksamkeit von DZNep in aggressiven B-Zell-
Lymphomen besser zu verstehen und die molekularen Mechanismen einer potentiellen 
Resistenz gegen DZNep aufzuklären. Darüber hinaus wollten wir prädiktive Biomarker 
ermitteln, die für den therapeutischen Einsatz, einer EZH2 Hemmung durch DZNep, von 
Bedeutung sein könnten. 
Unter Verwendung verschiedener molekularer, biochemischer und zellbiologischer Techniken 
wie Durchflusszytometrie, Western Blot, Sanger-Sequenzierung, Fluoreszenz-in-situ-
Hybridisierung (FISH) und Echtzeit-Reverse-Transkriptase-Polymerase-Kettenreaktion 
konnten wir zeigen, dass DZNep eine starke apoptotische und antiproliferative Wirkung auf 
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einen Teil der B-Zell-Lymphom-Zelllinien besitzt. Diese Effekte waren unabhängig vom 
Lymphomtyp, dem Vorhandensein von EZH2-Mutationen oder dem Vorhandensein bekannter 
prognostischer Lymphom-Biomarker wie MYC-, BCL2- oder BCL6-Translokationen. Um den 
molekularen Mechanismus zu untersuchen, der einer Resistenz gegen DZNep zugrunde liegt, 
haben wir aus einer zuvor DZNep-sensitiven B-Zell-Lymphom-Zelllinie einen DZNep-
resistenten Klon erzeugt, der nunmehr eine erworbene Resistenz gegen DZNep besitzt. Mit 
Hilfe dieses Klons sollen Ursachen, die zur Entwicklung des Resistenzmechanismus führen, 
besser verstanden werden. Bei der molekularen Charakterisierung zeigten sich zwischen dem 
generierten DZNep-resistenten Klon mit der Ursprungslinie (der Elternzelllinie) Unterschiede 
in Bezug auf Karyotyp, Genkopienanzahl, Proliferationsrate und der generellen Reaktion auf 
DZNep. Durch eine Klonalitätsuntersuchung der umgelagerten Immunglobulin-Gene konnten 
wir bestätigen, dass der DZNep-resistente Klon und die Elternzelllinie klonal identisch sind.  
Durch eine vollständige Exomsequenzierung des DZNep-resistenten Klon und seiner 
korrespondierenden Kontrolle, identifizierten wir im resistenten Klon eine genomische 
Amplifikation des AHCY-Gens. Durch verschiedene Methoden wie der 
Kopienzahlvariationstests, FISH, Genexpressionsanalyse und Immunhistochemie konnten wir 
diesen massiven AHCY-Gewinn auf DNA-, Chromosomen-, Transkriptions- und 
Translationsebene erfolgreich validieren. Wir konnten auch zeigen, dass in einer DZNep-
sensitiven Osteosarkom-Zelllinie die induzierte Überexpression von AHCY mit einer 
gesteigerten Resistenz gegen DZNep assoziiert ist. Die funktionelle Validierung einer AHCY-
Amplifikation in Lymphomzelllinien war aus technischen Gründen nicht erfolgreich. Aus 
Exomsequenzierungsdaten von DZNep-resistenten Zelllinien zeigten darüber hinaus in einer 
der resistenten Zelllinien eine Mutation im AHCY-Gen. Aus Online-Datenbanken wurde 
vorausgesagt, dass diese Mutation einen wahrscheinlich störenden Effekt auf die 
Proteinfunktion hat. 
Diese Arbeit zeigt, dass Veränderungen im AHCY-Gen einen möglichen 
Resistenzmechanismus gegen DZNep-Behandlung darstellen kann. Es zeigt darüber hinaus, 
dass sich die molekularen Mechanismen einer erworbenen DZNep-Resistenz deutlich von 
denen der intrinsischen Resistenz gegen DZNep unterscheiden können. Dennoch, könnte der 
genomische und proteomische Zustand von AHCY ein potenzieller Biomarker sein, der vor 






Cancers are a group of disorders that remain a major challenge of modern medicine until date. 
Although there has been series of advancements in our understanding of its biology, 
pathogenesis, diagnosis, management and treatment, they still present a serious health burden. 
In spite of available treatment options such as radiotherapy, immunotherapy, chemotherapy, 
hormone therapy and surgical procedures, many cancers have no cure. There are different types 
of cancers with different molecular mechanisms and treatment options. Many cancer entities 
for instance, lymphomas, still have a lot unknown about their etiology, pathogenesis, prevention 
and treatment.  
1.1 Lymphomas 
Lymphomas are a heterogeneous group of cancers, which originate from mature lymphoid cells. 
Despite progress in our knowledge of the management and therapeutic approaches for this 
group of disorders, this disease remains complex, with varying survival outcomes and treatment 
responses for the different lymphoma types (1). Lymphomas are grouped into two major 
categories; Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). The world health 
organization (WHO) further classifies lymphomas into over 80 different subtypes based on 
various criteria such as the histopathological, immunophenotypical, molecular and clinical 
pattern of this disease (2-5). HLs are characterized by the presence of large monoclonal and 
multinucleated B-cells called Reed-Sternberg cells (RSC) (6-11). They make up about 12% of 
all lymphomas and have high cure rates following early diagnosis and treatment (7, 12). Other 
lymphoma types without Reed-Sternberg cells present, are classified as NHLs. NHLs are more 
common than HLs, and patients with this disease have an overall 5-year survival of about 50 -
60% (13). The NHL are further subdivided into B-cell lymphoma (BCL; approximately 85% 
of cases) and T-cell lymphoma (TCL; approximately 15% of cases). Both lymphoma types may 
follow either an aggressive (fast growing) or indolent (slow-growing) clinical course, with the 
prognosis and treatment success in each case depending on the type and stage of the disease. 
For the scope of this work, we would address two major B-cell lymphomas with an aggressive 
clinical course, Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). 
1.1.1 Burkitt lymphoma (BL) 
BL is the most common form of NHL occurring in children and adolescents, with up to 30% of 
cases diagnosed in adults over the age of 60 (14, 15). There are three types of BL: sporadic BL, 
endemic BL and immunodeficiency-associated BL. Sporadic BL occurs worldwide, accounting 
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for 1-2% of NHL in adults, and about 30-50% of childhood lymphomas in the United States 
and Western Europe (4, 16, 17). Endemic BL occurs mainly in children of equatorial Africa 
and South America, with peak incidence at 4-7 years of age (16). The incidence in endemic 
regions correlates with the geographical distribution of endemic malaria, thus, its designation 
as endemic BL (16). Immunodeficiency-associated BL is mainly associated with individuals 
with human immunodeficiency virus (HIV) infection, those with congenital immunodeficiency, 
and allograft recipients (17-19). BLs proliferate rapidly and are characterized by deregulation 
of the MYC gene caused by a chromosomal translocation between chromosome 8 (MYC) and 
chromosome 14 (immunoglobulin heavy chain gene) in the majority of patients (15, 20). 
Although the presence of a MYC translocation is characteristic of BLs, this aberration is also 
present in a small proportion (5% to 15%) of DLBCL (21-23). In most cases, BL patients - 
especially of young age - have a favorable clinical outcome upon intensive treatment with 
immunochemotherapeutic combinations including Rituximab (20). 
1.1.2 Diffuse large B-cell lymphoma (DLBCL) 
DLBCLs are the most common type of NHLs worldwide (24). They constitute the largest group 
of aggressive B-cell tumors, and based on their gene expression profile, they can be subdivided 
into germinal center B‐cell (GCB) DLBCL, activated B‐cell (ABC) DLBCL, and primary 
mediastinal B-cell lymphoma (PMBL) (25-27). The GCB-type DLBCLs have a gene 
expression profile peculiar to germinal center B-cells, while the ABC-type DLBCLs express 
genes usually induced during activation of peripheral blood cells in vitro (25). PMBLs present 
gene signatures similar to that of RSCs of HL (26, 28).  
Whole exome and ribonucleic acid (RNA) sequencing has revealed that the mutational 
landscape in DLBCL is relatively complex and heterogeneous, with several genes and pathways 
deregulated in different patient groups (29-32). In GCB DLBCLs, one of these genomic 
aberrations involve translocation of the BCL2 gene, a phenomenon detected in about 30 - 45% 
of patients (33-35). This translocation, resulting in the juxtaposition of the BCL2 gene and the 
immunoglobulin heavy (IGH) chain locus t(14;18), leads to irregular functioning of the 
apoptosis regulator BCL2 (33, 36). In ABC DLBCLs, nuclear factor kappa-light-chain-
enhancer of activated B cells (NFkB) pathway activation and high levels of NFkB expression 
is characteristic, and its signaling is required for cell survival and proliferation (21, 37, 38). The 
most common chemotherapeutic agent used against DLBCL is the classical 
(C)yclophosphamide, (H)ydroxydaunorubicin, (O)ncovin, (P)rednisone (CHOP), or in 
combination with the monoclonal CD20 antibody (R)ituximab (R-CHOP). Stem cell 
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transplantation, radiation therapy as well as immunotherapy can be included in the treatment 
regimen for DLBCLs depending on the type and recurrence. Distinguishing the molecular 
DLBCL types appears to be clinically relevant. For instance, upon treatment with R-CHOP, 
patients with GCB DLBCL seem to have better survival outcome than patients with ABC 
DLBCL (27, 33, 39). Moreover, the overall 5-year survival of PMBL patients following 
chemotherapy is about 64% in comparison to GBC DLBCL (59%) and ABC DLBCL (30%) 
(28). 
 
Figure 1: Summary of the characteristics of BLs and DLBCLs.  
Although the survival rate of DLBCL patients treated with the standard R-CHOP regimen is 
around 50-70%, about 30% of relapse cases still occur and up to 30-50% of patients are not 
cured by this treatment (24, 40, 41). This necessitates the development of further targeted 
therapeutic options for patients - based on individual biomarkers - to address this heterogeneity. 
1.2 Epigenetics and lymphoma 
A principal mechanism in cancers - including lymphomas - is the presence of epigenetic 
alterations, which arise via deregulation of epigenetic switches and result in aberrant gene 
expression (42-44). These alterations modify the proliferation and differentiation programs of 
cells, resulting in tumor formation. Epigenetics deals with heritable variations in the DNA 
structure (which do not involve changes in the DNA sequence) that result in a change of gene 
expression patterns within organisms (45, 46). As an embryo develops, and during cell 
renewal/differentiation in adult cells, epigenetic control directs the outcome of different cell 
lineages (46-48). Epigenetic modifications may comprise histone modifications or alterations 
in the DNA methylation pattern (49-51).  
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Histones are basic cellular constituents composed of the core histones H2A, H2B, H3 and H4 
and the linker histone H1 (52-54). Histones arrange and package DNA into nucleosome units - 
the fundamental unit of chromatin. The nucleosome consists of DNA wound around two copies 
of each core histone, forming a central region and an exposed N-terminal tail extending out 
from its core (55). These histone tails play an important role via their interaction with a variety 
of proteins (56). Although nucleosomal packaging restricts the access of many regulatory 
proteins to the DNA, covalent post-translational modifications of the histone tails by 
acetylation, ubiquitination, phosphorylation and methylation, could alter gene expression (56-
61). Access of transcription factors to DNA and thus, gene transcription depends on the type 
and location of the histone tail modification. For example, methylation of lysine residues on 
histone tails can lead to gene activation or repression depending on the position of the lysine. 
Furthermore, different effects on the transcriptional status can be achieved depending on 
whether the lysine residue is mono-, di- or trimethylated (55). In contrast, acetylation of lysine 
residues on histones usually correlates with an active chromatin (62-65).  
Epigenetic alterations however, play a role in the development, pathogenesis and progression 
of tumors (66, 67). When there is an imbalance in epigenetic mechanisms regulating non-coding 
RNAs, DNA methylation, and post-translational histone tail modifications (68), tumor-
suppressor genes may become repressed. This, alongside with genomic alterations in enzymes 
regulating the cell cycle, and abnormal expression patterns of proteins playing a role in DNA 
repair and replication leads to tumor initiation and progression (69, 70). This further 
underscores the need for epigenetic-targeted therapy for the treatment of tumors.  
In the fight against lymphoma, epigenetic-based therapy is gaining attention as an alternative 
treatment option for patients (68, 71-73). Several epigenetic drugs have shown great preclinical 
potential for the treatment of lymphomas when used independently or as combination therapy 
(68). There are also clinical trials with various epigenetic therapeutics against lymphomas of 
B-cell origin (ClinicalTrials.gov identifier: NCT02951156; NCT02846935; NCT01120834; 
NCT00005639; NCT02951156). Some epigenetic drugs for instance, Vorinostat and Belinostat 
have been approved, and are now utilized in clinics for treatment of cutaneous T-cell lymphoma 
(68, 74) and refractory peripheral T-cell lymphoma patients (75) respectively.  
A unique set of proteins that modify chromatin structure, thereby, influencing the expression 
of genes are known as the Polycomb group proteins (PGPs). 
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1.2.1 Polycomb group proteins (PGPs) 
The PGPs were first discovered in the fruit fly Drosophila melanogaster, and are known to 
silence homeotic (Hox) genes during embryonic development by regulating the structure of 
chromatin (76-79). These proteins, which are evolutionarily conserved in plants and animals, 
are involved in establishing and maintaining gene repression and cell proliferation (76, 80). In 
mammals, the PGPs also function in X-chromosome inactivation, cell proliferation, 
tumorigenesis and hematopoiesis (76, 77, 81, 82). Mammalian PGPs consist of two different 
protein complexes - polycomb repressive complex 1 (PRC1) and polycomb repressive complex 
2 (PRC2), which target different genes involved in tumor suppression (83). 
PRC1 consists of the polycomb group RING fingers (PCGFs) whose functional roles have been 
highlighted (82, 84, 85). Although it is unclear how PRC1 mediates gene silencing (86), it is 
proposed that it compacts chromatin by catalyzing the monoubiquitylation of H2A at position 
lysine 119 (82, 87-91). In some cases, chromatin compaction by PRC1 occurs independent of 
enzyme activity (92).  
PRC2 comprises EZH1 or EZH2, embryonic ectoderm development (EED), suppressor of zeste 
12 (SUZ12) and retinoblastoma-binding protein p46 (RbAp46) (86, 87). PRC2 is a histone 
methyltransferase, which mediates gene silencing by selectively catalyzing the di- and 
trimethylation of lysine at position 27 of histone H3 (H3K27me2/3) (82, 87, 93-95). H3K27me3 
is a repressive histone mark that plays a role in regulating the expression of genes influencing 
cell proliferation and differentiation (96). Some additional proteins, such as adipocyte 
enhancer-binding protein 2 (AEBP2), polycomb-like (PCL) family protein, and Jumonji /AT-
rich interaction domain containing 2 (JARID2) sometimes associate with PRC2 complex to 
modulate and enhance its activity (87, 97-99).  
Although H3K27me3 acts as a mark for recruitment of PRC1 to create a more stable 
transcriptionally repressed state (92, 100-104), the mechanism of PRC2 recruitment to target 
genes is unclear (87). Recently, two models have been proposed, a PRC2:PRC1-dependent 
pathway and a PRC2:PRC1-independent pathway (105). PRC1 is recruited prior to PRC2 in 
the PRC2:PRC1-dependent model, while both PRC1 and PRC2 are recruited randomly or 
simultaneously to their targets in the described PRC2:PRC1-independent model (105). Both 
polycomb group complexes can induce the silencing of genes in synergy or independent of each 
other (106-108). The PGPs have been proposed as druggable targets for tumor therapy, and 
alterations in the PCR2 core component, EZH2, is suggested to have major prognostic 
implications for several cancers including lymphomas (109-111).  
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1.2.2 Enhancer of zeste homolog 1/2 (EZH1 / EZH2) 
EZH1 is a variant of EZH2, and it forms a different PRC2 complex with weak H3K27me3 
activity (108). EZH1 is poorly characterized in comparison to EZH2 and there are conflicting 
data about its function where in some cases, it contributes to transcriptional activation while in 
other instances, it leads to gene silencing (86, 108). EZH1 mediates a closed chromatin state 
via a mechanism which does not rely on the methyltransferase cofactor s-adenosylmethionine 
(SAM) (108, 112). EZH2 on the other hand, is a member of the (S)uppressor of variegation, 
(E)nhancer-of-zeste and (T)rithorax (SET) domain family that transfers methyl groups from 
SAM to lysine residues on histones, in a reaction resulting in a methylated lysine residue and 
S-adenosylhomocysteine (SAH) (113). EZH1 is expressed ubiquitously in non-proliferative 
adult cells while EZH2 expression is tightly linked with proliferation of transformed and non-
transformed human cells (112, 114). In differentiated cells however, EZH2 is downregulated 
(115). 
EZH2, whose gene is located on chromosome 7q36.1, is the main PRC2 component important 
for catalyzing histone lysine methyltransferase reactions (112, 116, 117). Additional evidence 
suggests that in cancer, EZH2 may act in a manner independent of PRC2 and histone 
methylation (97, 118, 119). EZH2 plays an important role in tumor initiation, progression, 
metastasis and drug resistance (31, 120, 121). Moreover, strong EZH2 expression has been 
linked with neoplastic transformation and aggressiveness of different cancer types (122-126). 
Furthermore, gain-of-function mutations including Tyr646, Ala682 and Ala692 are known for 
this gene, which lead to increased H3K27me3 (86, 97, 119, 127-129). Tyr646 indicates the 
replacement of the amino acid tyrosine at codon 646 (previously Tyr641). Ala682 means 
exchange of alanine at codon 682 (previously Ala677) and Ala692 implies the replacement of 
alanine at codon 692 (previously Ala687). In cancer therefore, EZH2 can serve as a useful 
prognostic biomarker (95, 124, 130). 
In follicular lymphoma for instance, these heterozygous EZH2 gain-of-function mutations 
occur in more than 25% of patients (127, 129). In DLBCL, particularly the GCB type, it occurs 
in almost 22% of patients (129). In addition, for melanoma, precisely cutaneous melanoma - 
the only solid cancer with Tyr646 mutation -, the frequency of this mutation is about 2 - 3% 
(131, 132). The overexpression of EZH2 has been shown to confer oncogenic potential in 
lymphoma, for instance natural killer/T-cell lymphoma (119), and other solid tumors such as 
breast (125), prostate cancer (133) and urothelial carcinoma (134). There is also a close 
association between EZH2 overexpression and a poor clinical outcome of cancer patients, for 
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example in patients with gastrointestinal DLBCL (128), prostate, breast and endometrial 
cancers (126), squamous cell carcinoma of the head and neck (135), as well as colorectal cancer 
(136). Since mutant EZH2 as well as overexpressed EZH2 contribute to cancer progression, 
therapies focusing on inhibiting EZH2 could be promising as alternatives for tumors treatment. 
1.2.3 EZH2 inhibitors 
Over the years, several small molecule EZH2 inhibitors have been discovered (table 1) and their 
apoptotic efficacy in NHL cell lines established. Most of these inhibitors however, promote 
apoptosis mainly in EZH2-mutated cell lines (137, 138). These EZH2 inhibitors are mainly 
direct EZH2 inhibitors with a high selectivity for EZH2 over EZH1 (97). The EZH2 inhibitor 
EPZ-6438 has been shown to have a remarkable efficacy in lymphomas and is currently in 
Phase II clinical trials on human subjects. EPZ-6438 however, is described to be more 
efficacious against lymphomas with mutated EZH2 (139). 3-Deazaneplanocin-A (DZNep) 
inhibits EZH2 indirectly, and although it is still in the preclinical phase of drug development, it 
stands out as having great potential for the treatment of tumors (140-143). 
Table 1: A list of EZH2 inhibitors, their mode of EZH2 inhibition and their status in drug development. 
Inhibitor Direct / indirect EZH2 inhibition Stage of drug development Reference 
EPZ005687 Direct (competes with SAM for binding on EZH2) Preclinical (137) 
EI1 Direct (competes with SAM for binding on EZH2) Preclinical (144) 
GSK343 Direct (competes with SAM for binding on EZH2) Preclinical (145) 
GSK126 Direct (competes with SAM for binding on EZH2) Clinical (Phase I) NCT02082977 (146) 
UNC1999 Direct (competes with SAM for binding on EZH2) Preclinical (138) 





Direct (competes with SAM for binding on EZH2) Preclinical (148) 
CPI-1205 Direct (competes with SAM for binding on EZH2) Clinical (Phase Ib/II) NCT02395601 (149, 150) 
CPI-169 Direct (competes with SAM for binding on EZH2) Preclinical (151) 
CPI-360 Direct (competes with SAM for binding on EZH2) Preclinical (152) 
EBI-2511 Direct (competes with SAM for binding on EZH2) Preclinical (153) 
ZLD1039 Direct (competes with SAM for binding on EZH2) Preclinical (154) 
DZNep Indirect (inhibits S-adenosylhomocysteine hydrolase 
and thus, SAM-dependent methyltransferases) 
Preclinical (155-158) 
SAM: S-adenosylmethionine. The above table is an updated version of the list adapted from Kim K. H. and Roberts 
C. W. M. (97). 
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1.3 3-Deazaneplanocin A (DZNep) and S-adenosylhomocysteine hydrolase (AHCY) 
DZNep is an inhibitor of EZH2 discovered over 30 years ago, and has been associated with its 
cytotoxic effects in cancer (157, 158). However, preclinical studies on this inhibitor is still 
ongoing due to questions concerning its specificity, nephrotoxicity and short plasma half-life 
(159, 160). DZNep indirectly inhibits EZH2 by competitively blocking the activity of AHCY.  
AHCY is associated with DNA methylation and it catalyzes the reversible reaction in which 
SAH is hydrolyzed to adenosine and homocysteine (161, 162). Altered AHCY activity has been 
linked to diverse outcomes in different cancer entities (163-166). During histone lysine 
methylation (figure 2), SAM donates methyl groups, and is metabolized to SAH by 
methyltransferases (162). DZNep directly inhibits AHCY causing buildup of SAH levels within 
cells, and due to increased SAH, there is a subsequent rise in SAM due to feedback inhibition 
by SAH on methyltransferases (158, 159, 162). Methyltransferases that require the donation of 
methyl groups from SAM, such as EZH2 are hence impeded. EZH2 inhibition by DZNep leads 
to the down regulation of H3K27me3. The lifting of this repressive histone mark from tumor 
suppressors, differentiation promoting and apoptosis promoting genes is thought to be the 
mechanism through which DZNep exerts its anti-tumor effects.  
 
Figure 2: How DZNep indirectly inhibits EZH2. SAM donates methyl (Me) groups during methylation 
reactions. EZH2 catalyzes the trimethylation of H3K27, while SAM is metabolized to SAH. AHCY catalyzes the 
reversible hydrolysis of SAH to adenosine and homocysteine. DZNep directly inhibits AHCY, causing buildup of 
SAH levels within cells, and due to increased SAH, there is a subsequent feedback inhibition of EZH2. Figure was 
adapted from Miranda T. B. et al., (159). 
Indeed, DZNep inhibits EZH2, leading to the lowering of H3K27me3 and induction of 
apoptosis in different cancer cell lines as well as primary tumor cells (167-171). The histone 
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demethylation brought about by DZNep revives genes repressed by PRC2 in tumor cells, 
consequently promoting apoptosis in these cells (167).  
We are aware that the inhibitory effects of DZNep on histone methylation are not exclusively 
specific to EZH2 (97, 159, 172), nevertheless, there is plausibility for its clinical use. For one 
thing, the changes effected by DZNep are both non-heritable and reversible (159). Moreover, 
in light of our knowledge of multiple histone methyltransferases whose overexpression have 
been linked to cancer, as well as the benefit of dual EZH1 and EZH2 inhibition (173-177), 
DZNep may be a good option in such cases which necessitate the inhibition of more than one 
of these aberrant histone methyltransferases. In addition, not only does DZNep have better 
clinical potential in comparison to other AHCY inhibitors but also, the in vivo evaluation of the 
pharmacokinetic properties of DZNep shows encouraging results for its progress into clinical 
usage (142, 159). 
Despite the number of promising in vitro studies with DZNep, we would not fail to mention the 
most frequent problem associated with cancer chemotherapy - the issue of drug resistance. 
Mechanisms of resistance to cancer chemotherapy are well known (178, 179), and they remain 
a great barrier for many chemotherapeutic regimens. DZNep has already proven to have a good 
perspective for cancer treatment. However, as more preclinical studies with DZNep evolve, to 
further explore its potential, one also needs to understand if acquired resistance could occur 
during its administration. If so, the molecular mechanisms behind this resistance and ways in 
which this problem could be averted. 
1.4 Aims of the study 
This study aims to investigate the in vitro effects of DZNep as an EZH2 inhibitor in aggressive 
B-cell lymphomas. Furthermore, we aim at elucidating the molecular mechanism of resistance 
to DZNep, and at identifying biomarkers that could be of prognostic relevance for EZH2-based 














MATERIALS AND METHODS 
2.1 Cell lines and cell culture  
We used seven DLBCL cell lines KARPAS-422 (ACC-32), SU-DHL-10 (ACC-576), 
CARNAVAL (ACC-724), WSU-DLCL-2 (ACC-575), U-2932 R1, U-2932 R2, HT (ACC-
567), five BL cell lines DG-75 (ACC-83), BLUE-1 (ACC-594), BL-2 (ACC-625), CA-46 
(ACC-73), BL-41 (ACC-160) as described (180), and one osteosarcoma cell line U-2-OS (ACC 
785). The cell lines were obtained from the German collection of microorganisms and cell 
cultures (DSMZ), Germany. U-2932 R1 and U-2932 R2 were provided by Dr. Hilmar 
Quentmeier (181), DSMZ, Germany. The lymphoma cell lines were cultured in RPMI 1640 
medium (Life Technologies GmbH/ThermoFisher Scientific, Germany) augmented with 20% 
fetal calf serum (PAN-Biotech, Germany) as described (180). U-2-OS cell line was cultured in 
Dulbecco's modified Eagle's medium (PAN-Biotech, Germany) supplemented with 10% fetal 
calf serum and 1% Penicillin-streptomycin (Biochrom GmbH, Germany). Cell lines were 
screened and confirmed negative for mycoplasma contamination using the MycoAlert 
Mycoplasma detection kit (Lonza, Germany), and following the manufacturer’s 
recommendations. Cell culture was done under sterile conditions and the cell lines were 
incubated at 37°C and 5% CO2.  
2.2 Drug preparation 
The EZH2 inhibitors DZNep (Selleckchem, Germany) and EPZ-6438 (Selleckchem, Germany) 
were dissolved in sterile water and dimethyl sulfoxide (DMSO) (SERVA Electrophoresis 
GmbH, Germany) respectively as described (180). 
2.3 Flow cytometry 
Flow cytometry was carried out with BD Accuri C6 flow cytometer (BD Biosciences, USA) 
for determination of the percentage of apoptotic cells, immunophenotyping, proliferation assay 
and doubling time analysis. 
Apoptosis measurement was performed as already described (180). Immunophenotyping for 
the identification of cell surface cluster of differentiation (CD) markers highly specific for B-
cells - CD19 and CD20 - was performed similarly with the method described for the 
measurement of apoptotic cells, except that in this case, the binding buffer and corresponding 
anti-CD antibody were mixed at a ratio of 20:1 respectively. Cells were stained with fluorescein 
isothiocyanate (FITC)-conjugated anti-human CD19 monoclonal antibody (Dako Denmark 
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A/S, Denmark) and Alexafluor 488-conjugated anti-human CD20 monoclonal antibody 
(Biolegend, USA). Negative controls used include mouse IgG3 (Dako Denmark A/S, Denmark) 
and Alexafluor 488 Mouse IgG2b, κ isotype control (Biolegend, USA) respectively. Data was 
analyzed using the BD Accuri C6 software (BD Biosciences, USA). 
Cell proliferation assay was carried out as previously reported (180). Proliferation was also 
analyzed at the RNA level using synthesized complementary DNA (cDNA) (see description in 
section 2.7) from the respective cell lines and checking for changes in key proliferation genes. 
The method is further described in section 2.7.1. 
Experiments for the determination of the doubling time of the cell lines was carried out as 
recorded (see description in Akpa C. A. et al., manuscript in review (appendix C)).  
2.4 Generation of a DZNep-resistant BLUE-1 variant 
A DZNep-sensitive BL cell line, BLUE-1 was selected for the generation of a DZNep-resistant 
clone (figure 3) as detailed in Akpa C. A. et al., manuscript in review (appendix C).  
Confirmation of the identities of the parent cell line, the generated DZNep-resistant cell line 
and its control was done at 3 levels: identity based on immunophenotyping, the immunoglobulin 
heavy chain (IGH) gene rearrangement (described in section 2.8), and short tandem repeat 
(STR) profile (described in section 2.13).  
 
Figure 3. Generation of a DZNep-resistant BLUE-1 clone. The above figure was adapted from Akpa C. A. et 
al., manuscript in review (see appendix C). 
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2.5 Inhibitory concentration 50 (IC50) analysis 
The IC50 was analyzed as described (180). DZNep concentrations above 10 µM were not used 
in accordance with published information (169, 182) as very large amount of the inhibitor might 
cause cytotoxic effects rather than programmed cell death induced by the biological 
consequences of EZH2 inhibition.  
2.6 Cell fractionation and Western blotting 
Nuclear and cytoplasmic cellular fractions were separated using NE-PER nuclear and 
cytoplasmic extraction reagents (ThermoFisher Scientific, Germany), adhering to the 
manufacturer’s protocol. Cell lysis and Western blot was performed as described (180). Details 
of the antibodies used for performing Western blot are listed in table 2.  






Western blot Immunophenotyping Immunohistochemistry     
CD19  ✓  Dako Denmark A/S F0768 
CD20  ✓  Biolegend 302316 
GAPDH ✓   Cell Signaling Technology 2118S 
EZH2 ✓   Cell Signaling Technology 5246S 
H3K27me3 ✓   Cell Signaling Technology 9733S 
Beta-actin ✓   Cell Signaling Technology 4967S 
Histone 3 ✓   Cell Signaling Technology 3638S 
Cleaved PARP ✓   Cell Signaling Technology 9541S 
AHCY ✓  ✓ OriGene TA332593 
Mouse IgG3   ✓  Dako Denmark A/S X954 
Mouse IgG2b  ✓  Biolegend 400329 
                             Secondary antibody 
Anti-rabbit HRP-
conjugated ✓     GE Healthcare NA934V 
Anti-mouse HRP-
conjugated ✓     Agilent P0447 
The above table includes (antibody) information adapted from Akpa C. A. et al., (180), and Akpa C. A. et al., 
manuscript in review (see appendix C).  
2.7 RNA extraction and real-time reverse transcriptase polymerase chain reaction (RT-
PCR) 
RNA isolation and cDNA synthesis were performed as already reported ((180, 183). See 
method also in Akpa C. A. et al., manuscript in review (appendix C)).  
2.7.1 Proliferation assay 
To check the impact of DZNep on proliferation, we examined the expression of select genes 
that play an important role in cellular proliferation. They include proliferating cell nuclear 
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antigen (PCNA) and cyclin-dependent kinase 2 (CDK2). Beta 2 microglobulin (B2M) gene was 
used as an endogenous control. 
The primers for the above genes were designed with Primer-BLAST, a search tool hosted by 
the National Center for Biotechnology Information (NCBI), USA as described (180), and were 
purchased from Eurofins MWG, Germany. Information on the forward and reverse primer 
sequences for each target can be found in table 3. During the real-time PCR, B2M gene was 
amplified in parallel with both proliferation genes of interest and the run for each sample was 
performed in triplicates. The comparative ΔΔCt method (184) was used for relative mRNA 
quantification.  
Table 3. Details of primers used for proliferation assay and mutation validation. 
cDNA 
Target 
Target Forward sequence Reverse sequence Application Company 
































Table includes EZH2 primer sequences adapted from Akpa C. A. et al., (180). 
2.7.2 AHCY gene expression assay 
To determine expression of AHCY at the RNA level, the AHCY TaqMan gene expression assay 
was used. For this assay, B2M, succinate dehydrogenase (SDHA), and AHCY TaqMan gene 
expression assays, as well as the TaqMan gene expression master mix (all from ThermoFisher 
Scientific, Germany) were used (see details in table 4). The assay was performed following the 
manufacturer’s protocol and the real-time PCR was done with the StepOnePlus real-time PCR 
system (ThermoFisher Scientific, Germany). B2M and SDHA served as reference genes and 
were amplified in parallel with AHCY. Using the Step-One software version 2.3, relative mRNA 







Table 4. List of TaqMan assays utilized in analysis of gene expression and copy number variation (CNV). 
 Targets Assay ID Type Company 
cDNA target 
AHCY Hs00898137_g1 Gene expression assay ThermoFisher Scientific 
B2M* Hs00984230_m1 Gene expression assay ThermoFisher Scientific 
SDHA* Hs00417200_m1 Gene expression assay ThermoFisher Scientific 
gDNA target 
AHCY Hs02422126_cn CNV assay ThermoFisher Scientific 
AHCY Hs02512802_cn CNV assay ThermoFisher Scientific 
*Endogenous control 
Details of the gene expression assays and the CNV assay (Hs02422126_cn) were adapted from Akpa C. A. et al., 
manuscript in review (appendix C). 
2.8 DNA extraction, polymerase chain reaction (PCR) and Sanger sequencing 
Genomic DNA was extracted with the QIAamp DNA Mini Kit (Qiagen, Germany), following 
the instructions of the manufacturer as recorded (180).  
Design of EZH2 primers was done with the Primer BLAST tool (NCBI). The forward and 
reverse primer sequences used for the detection of EZH2 point mutation at the genomic level 
can be found in table 3. These primers span the EZH2 mutation hotspot Tyr646 (product length 
of 256 base pairs). The primers used to validate the EZH2 point mutations on the RNA (cDNA) 
level are also included in table 3. The latter primer sequences interrogates the EZH2 mutational 
hotspots Tyr646, Ala682 and Ala692 (product length of 340 base pairs). 
To validate the expression of mutated AHCY (in the DZNep-resistant cell line HT) at the RNA 
(cDNA) level, forward and reverse primers spanning the exon 3 region of AHCY were designed 
using the Primer 3 software (185, 186). These primer sequences, which yield a product with a 
length of 190 base pairs, are included in table 3.  
PCR, clean-up of PCR products and Sanger sequencing was performed as described (180).  
For the confirmation of the identity of the resistant BLUE-1 clone, B-cell clonality studies was 
performed for BLUE-1, BLUE-1K10 and BLUE-1R10. To this end, a multiplex PCR using 
IGH-specific primer sets was performed following the standard protocol of the 
EuroClonality/BIOMED-2 study, BMH4-CT98-3936 (187). Six primers for the framework 
(FR) 1 region of the variable (V) IGH gene segment (FR1-VH), seven FR2-VH primers and 
seven FR3-VH primers were independently mixed with a 6-carboxyfluorescein (6-FAM)-
labelled Joining (JH) primer in three separate combinations. Details on the various primers are 




Table 5. Details of the primers used for the confirmation of the B-cell clonality of BLUE-1, BLUE-1K10 and 
BLUE-1R10. 
    Primers Company of purchase 
FR 1 
FR1 V IGH 5’-GGCCTCAGTGAAGGTCTCCTGCAAG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR1 V IGH 5’-TCTGGTCCTACGCTGGTGAAACCCA-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR1 V IGH 5’-CTGGGGGGTCCCTGAGACTCTCCTG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR1 V IGH 5’-CTTCGGAGACCCTGTCCCTCACCTG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR1 V IGH 5’-CGGGGAGTCTCTGAAGATCTCCTGT-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR1 V IGH 5’-TCGCAGACCCTCTCACTCACCTGTG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR 2 
FR2 V IGH 5’-CTGGGTGCGACAGGCCCCTGGACAA-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR2 V IGH 5’-TGGATCCGTCAGCCCCCAGGGAAGG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR2 V IGH 5’-GGTCCGCCAGGCTCCAGGGAA-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR2 V IGH 5’-TGGATCCGCCAGCCCCCAGGGAAGG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR2 V IGH 5’-GGGTGCGCCAGATGCCCGGGAAAGG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR2 V IGH 5’-TGGATCAGGCAGTCCCCATCGAGAG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR2 V IGH 5’-TTGGGTGCGACAGGCCCCTGGACAA-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR 3 
FR3 V IGH 5’ TGG AGC TGA GCA GCC TGA GAT CTG A 3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR3 V IGH 5’-CAATGACCAACATGGACCCTGTGGA-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR3 V IGH 5’-TCTGCAAATGAACAGCCTGAGAGCC-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR3 V IGH 5’-GAGCTCTGTGACCGCCGCGGACACG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR3 V IGH 5’-CAGCACCGCCTACCTGCAGTGGAGC-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR3 V IGH 5’-GTTCTCCCTGCAGCTGAACTCTGTG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
FR3 V IGH 5’-CAGCACGGCATATCTGCAGATCAG-3’ 
TIB MOLBIOL Syntheselabor GmbH 
  
JH-22 
FAM J IGH 5’-6FAM-CTTACCTGAGGAGACGGTGACC-3’ TIB MOLBIOL Syntheselabor GmbH 
Primers used were those from the EuroClonality/BIOMED-2 collaborative study (van Dongen J. J. M. et al., (187)). 
 
2.9 Fluorescence in situ hybridization (FISH) studies  
Sections of cell lines that were formalin-fixed and paraffin-embedded (FFPE), as well as cell 
line cytospins were used for FISH studies as already described (180, 188, 189). This was done 
in collaboration with Dr. Dido Lenze of the Molecular Pathology department, Charité - 
University Hospital, Berlin, Germany.  
AHCY amplification was detected using AHCY gene-specific probe and chromosome 20-control 
(centromeric) probes (both of which were purchased from Empire Genomics, USA) as detailed 
in Akpa C. A. et al., manuscript in review (see appendix C). 
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2.10 Whole exome sequencing (WES) 
WES was performed on genomic DNA obtained from BLUE-K10 and BLUE-1R10 at the core 
facility Genomics, Berlin Institute of Health (BIH), Berlin, Germany. Next generation 
sequencing libraries, cluster generation, template sequencing, data analysis and copy number 
variation analysis were carried out as reported (Akpa C. A. et al., manuscript in review 
(appendix C)). Data analysis was carried out in collaboration with the research group of Dr. 
Dieter Beule (BIH/Charité Core Unit Bioinformatics, Berlin, Germany).  
2.11 Copy number variation (CNV) assay 
AHCY CNV assay was carried out with high-quality genomic DNA using 2 independent 
Taqman assays (see details in table 4), one (assay ID: Hs02422126_cn), overlapping intron 7 
and exon 8 and the other (assay ID: Hs02512802_cn) overlapping intron 3 and exon 3 (both on 
reference genome GRCh37). AHCY CNV analysis was also carried out using primary patient 
DNA samples. For the use of patient samples a positive statement from the Institutional Review 
Board of Charité - Berlin (EA4/104/11) was obtained. The TaqMan CNV assay and data 
analysis was performed as recorded (Akpa C. A. et al., manuscript in review (appendix C)).  
CNV analysis was also done using genome-wide DNA methylation array data (refer to section 
2.12). The ‘conumee’ R package in Bioconductor (190) was used for the production of copy 
number plots as recorded (Akpa C. A. et al., manuscript in review (appendix C)). This analysis 
was performed in collaboration with Prof. David Capper from the Institute of Neuropathology, 
Charité - University Hospital, Berlin, Germany. Details of the methods for this analysis has 
been published (191).  
2.12 Global DNA methylation analysis 
Two methods were used to detect global changes in the DNA methylation status of the cell 
lines, BLUE-1, BLUE-1K10 and BLUE-1R10.  
Initially, the percentage of DNA methylation was evaluated using the MethylFlash Global DNA 
methylation (5-mC) enzyme-linked immunosorbent assay (ELISA) Easy Kit (Colorimetric) 
purchased from EpiGentek, USA. The product protocol was followed accordingly, and global 
methylated DNA quantification was done following a colorimetric approach by reading the 
absorbance at 450 nm wavelength with the Emax plus microplate spectrophotometer 
(Molecular devices, USA).  
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Subsequently, genome-wide DNA methylation analysis was done in collaboration with Prof. 
David Capper (Neuropathology, Charité - University Hospital, Berlin, Germany) with the 
Infinium MethylationEPIC BeadChip (Illumina, USA) (191). Methylation data from concerned 
lymphoma cell lines were analyzed and compared with the methylation data from primary 
DLBCL and plasmacytomas from skull and spinal lesions (192) using R (193). 
Bioinformatics.Expert UG, Berlin, Germany, performed further analysis of Infinium EPIC 
datasets, including data processing, differential methylation analysis, and comparison of 
differentially methylated probes. Differentially methylated probes were defined by having an 
adjusted p-value of below 0.01.  
2.13 Cytogenetics, OncoScan CNV assay and metabolomics assay 
The authenticity of BLUE-1, BLUE-1K10 and BLUE-1R10 were confirmed by determining 
the STR profile as already published (194). While cytogenetic investigation was performed on 
these three cell lines as described (195), OncoScan CNV assays were done as reported (194). 
The criteria used to define a copy number alteration include chromosomal changes covering a 
minimum of 20 probes, having a size of 100kb or more, showing a median log2Ratio of +/- 0.3, 
and possessing a copy number neutral loss of heterozygosity (CNN-LOH) of more than 5Mb 
(194). STR profiling, conventional cytogenetics and OncoScan CNV analysis was carried out 
in collaboration with the research group of Prof. Reiner Siebert at the Institute of Human 
Genetics, University of Ulm, Germany. Intermediates of methionine and polyamine metabolism 
in BLUE-1, BLUE-1K10, BLUE-1R10, BLUE-1K12 and BLUE-1R12 were analyzed in 
collaboration with the research group of Prof. Peter J. Oefner of the Institute of Functional 
Genomics, University of Regensburg, Regensburg, Germany. The metabolites were measured 
using a procedure already reported (196). The methods for STR profiling of the cell lines, 
cytogenetics, OncoScan CNV analysis and metabolomics studies have already been reported 
(Akpa C. A. et al., manuscript in review (appendix C)). 
2.14 Immunohistochemistry (IHC) 
Immunohistochemistry for the analysis of AHCY protein expression was performed on FFPE 
sections of cell lines as described (197). The anti-AHCY antibody used for IHC is shown in 




2.15 Stable AHCY transfection of cell lines 
Human AHCY ORF mammalian expression plasmid and pCMV3-C-FLAG negative control 
plasmid (both from Biozol Diagnostica Vertrieb GmbH, Germany) were used to transfect cell 
lines. Both plasmids, which are under the control of a CMV promoter, carry the Kanamycin 
and Hygromycin resistance genes. Competent DH5α E. coli cells were transformed using both 
plasmids. Selection of potent plasmids was done using a medium with Kanamycin. The plasmid 
DNA was isolated and purified using the Qiagen Plasmid Maxi kit (Qiagen, Germany). 
2.15.1 AHCY Knockdown 
Mission endoribonuclease-prepared small interfering RNA (esiRNA) (from Sigma-
Aldrich/Merck, Germany) targeting human AHCY, and an ON-TARGETplus Non-targeting 
negative control pool (ThermoFisher Scientific/Dharmacon, Germany) were used to transfect 
5x106 vital BLUE-1R10 cells in a 6-well cell culture plate. Using program D-23 on the 
Nucleofector 2b Device (Lonza Group AG, Germany) and following the manufacturer’s 
protocol, the Amaxa Cell line Nucleofector Kit C (Lonza Group AG, Germany) was used for 
the electroporation procedure. Knockdown efficiency was analyzed using Western blot while 
gene expression analysis following AHCY knockdown was done by real-time RT-PCR using 
AHCY and B2M TaqMan gene expression assays (see table 4). 
2.15.2 AHCY overexpression 
Overexpression of AHCY was performed in collaboration with the research group of Prof. 
Claus Scheidereit (Max-Delbrück-Centrum for Molecular Medicine, Berlin, Germany). The 
respective lymphoma cell lines as well as the osteosarcoma cell line (U-2-OS) were transfected 
with the respective plasmids (described in 2.15) using Lipofectamine 2000 transfection reagent 
(ThermoFisher Scientific, Germany) following the reagent protocol of the manufacturer. Stably 
transfected clones overexpressing the insert were selected using 200 µg/ml hygromycin B 
(Sigma-Aldrich/Merck, Germany). The hygromycin B-resistant cells were propagated in 
hygromycin B-positive medium for at least 10 days. They were harvested afterwards, and 
AHCY overexpression was confirmed by Western blotting. 
2.16 Statistical analysis 
GraphPad Prism 5 (GraphPad Software, California, USA) was used to perform statistical 
analysis. Comparisons between two groups were done using the Mann-Whitney U test (two-
tailed) while group comparisons were done with one-way ANOVA (Tukey post-hoc test). 





3.1. DZNep causes apoptosis in lymphoma cell lines  
To determine the apoptotic effect of DZNep in lymphoma cells, we treated selected cell lines 
with increasing DZNep concentrations (0 - 10 µM). We recorded a gradual increase in the 
percentage of apoptotic cells measured with increasing DZNep concentrations (figure 4A). 
Subsequent treatment of cell lines was carried out with 5 µM DZNep since the percentage of 
apoptotic cells recorded (and the expression of cleaved poly (ADP-ribose) polymerase (PARP, 
a known molecular indicator of apoptosis induction)) were only minimal between DZNep 
concentrations of 5 µM and 10 µM.  
 
Figure 4A. DZNep-mediated apoptosis depends on the drug concentration. Three cell lines that undergo 
apoptosis upon treatment with DZNep (BLUE-1, BL-2 and Carnaval) were treated with increasing concentrations 
of the inhibitor for 72 hours. Flow cytometry was employed for the measurement of the percentage of apoptotic 
cells. The results of three independent experiments are shown, and data is presented as mean plus standard 
deviation (SD). Figure was adapted from Akpa C. A. et al., (180).  
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To show the time dependence of apoptosis mediated by DZNep, 12 lymphoma cell lines 
(consisting of BLs and DLBCLs) were treated with 5 µM DZNep. Measurement of apoptotic 
cells was done at 24 hours, 48 hours and 72 hours following treatments. At 72 hours, we could 
clearly observe greater than 20% apoptotic cells measured for many DZNep-sensitive cell lines 
(Carnaval, U-2932 R2, BL-41, BL-2, SU-DHL-10, WSU-DLCL-2, KARPAS-422 and BLUE-
1) (figure 4B). Some cell lines (CA-46 and DG-75) however, showed a low percentage of 
apoptotic cells even at 72 hours after DZNep treatment. We thus made further DZNep 
treatments for 72 hours since after this time, there was a high tendency that the cell number of 
the untreated controls could exceed the maximum density stipulated by the DSMZ for optimal 
growth of the cells. 
 
Figure 4B. DZNep-mediated apoptosis is time-dependent. 5 µM DZNep was administered to 12 B-cell 
lymphoma cell lines, and the percentage of apoptotic cells measured using flow cytometry at 24 hours, 48 hours 
and 72 hours as reported (180). The values shown were normalized with those of the controls. Figure was adapted 
from Akpa C. A. et al., (180). 
Having established the optimal concentration and time point for DZNep treatment, the 12 
lymphoma cell lines, were administered 5 µM DZNep for 72 hours. Upon measurement of the 
percentage of apoptotic cells, we observed a gradation in the response of the cell lines to 





Figure 4C. Effect of DZNep on apoptosis in B-cell lymphoma cell lines. 12 lymphoma cell lines were either 
untreated or treated for 72 hours with 5 µM DZNep, and apoptosis was measured afterwards with flow cytometry. 
The above data is presented as mean plus SD from 3 independent replicates. Figure adapted from Akpa C. A. et 
al., (180). 
The need to better classify the cell lines as DZNep-sensitive or DZNep-resistant arose following 
the observation that some cell lines only reacted weakly to apoptosis following DZNep 
exposure using already established culture conditions. To achieve this, we determined the IC50. 
Based on our IC50 definition (180), 7 cell lines were grouped as DZNep-sensitive (IC50 between 
2 – 10 µM), 3 cell lines were grouped as DZNep-resistant (IC50 > 15 µM), while 2 cell lines fell 
within an intermediate group (IC50 between 10 – 15 µM) (figure 4D). We are aware that these 
groups demonstrate gradual concentration differences. However, to correlate the reactivity of 




Figure 4D. DZNep-sensitive and DZNep-resistant cell lines based on IC50. The IC50 for each cell line was 
determined, and the cell lines were grouped into a DZNep-sensitive, a DZNep-resistant and an intermediate group. 
The above measurement is presented as mean plus SD of triplicate experiments. Figure adapted from Akpa C. A. 
et al., (180). 
To use another method for confirmation that cell lines designated as DZNep-resistant based on 
the IC50 results were indeed resistant, Western blot showing PARP cleavage expression was 
performed using two representative DZNep-resistant cell lines. These cell lines, CA-46 and HT 
were treated with increasing DZNep concentrations until 10 µM. The cells were harvested, the 
percentage of apoptotic cells determined with flow cytometry, and total cell protein lysate from 
the cells used for Western blot analysis. The results showed that both DZNep-resistant cell lines 
display minimal changes in the level of cleaved PARP expression after DZNep treatment in 




Figure 4E. DZNep-resistant cell lines (as determined by IC50 values) CA-46 and HT show minimal apoptotic 
cells and comparable cleaved PARP expression following exposure to DZNep. The upper panel shows the 
percentage of apoptotic cells as measured by flow cytometry. The lower panel shows the Western blot result 
following the analysis of protein lysate isolated from DZNep treated cells and their controls. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as a loading control. 
 
3.2. Sensitivity to DZNep is independent of the EZH2 mutation status, lymphoma type, 
and MYC, BCL2 and BCL6 translocations  
Having shown that DZNep possesses a robust in vitro apoptotic capacity, we sought to address 
whether the sensitivity or resistance of the cell lines to DZNep depends on the type of 
lymphoma, the EZH2 mutation status or the presence of MYC, BCL2 or BCL6 translocations.  
We first determined the EZH2 mutation status of the cell lines, focusing on the frequently 
reported EZH2 mutation sites already known (Tyr646, Ala682 and Ala692). In 4 out of the 12 
cell lines analyzed, the Tyr646 mutation was detected (figure 5A). This mutation was expressed 
in these cell lines at the RNA (cDNA) level as demonstrated by Sanger sequencing. The amino 
acid change from Tyrosine to Phenylalanine was observed in the cell lines SU-DHL-10, 
34 
 
Carnaval and WSU-DLCL-2, while a change from Tyrosine to Asparagine was noted in 
KARPAS-422. None of the cell lines had EZH2 mutated at Ala682 and Ala692 hotspots.  
 
Figure 5A. Summary of EZH2 mutations detected in the cell lines at the EZH2 mutation hotspot Tyr646. 
Results of the lymphoma cell lines that expressed EZH2 Tyr646 mutation (SU-DHL-10, KARPAS-422, Carnaval 
and WSU-DLCL-2) as determined by Sanger sequencing. Figure adapted from Akpa C. A. et al., (180). 
We also performed FISH analysis on sections of FFPE cell line blocks and cytospins of cell 
lines to determine cell lines which have or which do not have MYC, BCL2 and BCL6 
translocations. The results (figure 5B) reveal cell lines which harbor (+) or do not harbor (-) the 
respective translocations. MYC translocations for the cell lines DG-75, CA-46 and SU-DHL-10 
was confirmed from the DSMZ information on the cell lines (found on DSMZ website with the 
cell line identification numbers: ACC 83, ACC 73 and ACC 576 respectively). MYC 
translocation status of the cell lines HT and WSU-DLCL-2 was not investigated since this is 






Figure 5B. FISH data showing cell lines which harbor (+) or do not harbor (-) (i) MYC (ii) BCL2 and (iii) 
BCL6 translocations. Figure adapted from Akpa C. A. et al., (180). 
Integrating the data from the lymphoma type, the EZH2 mutation status and MYC, BCL2 and 
BCL6 translocation status, there was no correlation between DZNep sensitivity or resistance 
and these mentioned factors. Nonetheless, we observed that the Tyr646 mutation is expressed 
predominantly in BCL2-translocated DLBCLs (table 6). 
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Table 6. Association between the lymphoma type, the EZH2 mutation status, the MYC, BCL2 and BCL6 
translocation status and DZNep sensitivity. 

















Carnaval DLBCL + TAC→TTC 
(Tyr641Phe) 
+ + - + 2.5 
U-2932 R2 DLBCL - - + - - + 3.0 
BL-41 BL - - + - - + 3.8 
BL-2 BL - - + - - + 3.8 
SU-DHL-10 DLBCL + TAC→TTC 
(Tyr646Phe) 
+ + - + 5.4 
KARPAS-422 DLBCL + TAC→AAC 
(Tyr646Asn) 
- + - + 6.3 
BLUE-1 BL - - + - - + 8.7 
WSU-DLCL-2 DLBCL + TAC→TTC 
(Tyr646Phe) 
+ + + + 10.1 
U-2932 R1 DLBCL - - - - - + 13.2 
HT DLBCL - - - - - - 17.8 
DG-75 BL - - + - - - 27.4 
CA-46 BL - - + - - - 33.4 
The table was adapted from Akpa C. A. et al., (180). 
Further grouping of the cell lines with focus on the strength of apoptosis measured upon DZNep 
treatment and their EZH2 mutation status (Tyr646) showed low correlation between these two 
variables. Nevertheless, we showed that cell lines resistant to DZNep (with no to weak 
apoptosis) did not have EZH2 mutated at Tyr646 (figure 5C). 
 
Figure 5C. Grouping of the 12 lymphoma cell lines based on the strength of apoptosis measured following 




3.3 Consequence of mutated EZH2 on H3K27me3 in B-cell lymphoma cell lines 
To check the impact of EZH2 mutation on H3K27me3 mark in the genome, we performed 
Western blot assay with extracted protein lysates from EZH2-mutated and wild-type EZH2 
lymphoma cell lines. We showed that this gain-of-function mutation is associated with an 
increased H3K27me3 in the cell, as cell lines with the Tyr646 mutation had increased 
H3K27me3 protein expression (figure 6). 
 
Figure 6. Cell lines with mutated EZH2 have H3K27me3 overexpression relative to cell lines with wild-type 
EZH2. (A) Western blot of whole cell protein lysates from the 12 lymphoma cell lines used in this work, showing 
EZH2 and H3K27me3 expression. GAPDH used as a loading control. (B) EZH2 and H3K27me3 densitometric 
quantification (SU-DHL-10 served as a reference cell line while GAPDH was used for data normalization). Figure 
adapted from Akpa C. A. et al., (180). 
3.4 DZNep induces apoptosis by the inhibition of EZH2 and downregulation of 
H3K27me3 in lymphoma 
To understand whether DZNep indeed inhibits EZH2 and causes subsequent H3K27me3 
downregulation, 3 cell lines, one EZH2-mutated cell line (KARPAS-422) and two wild-type 
EZH2 cell lines (BL-2 and BLUE-1) were treated with increasing concentrations of DZNep. 
Total protein lysates were prepared from the cells and used for Western blot analysis. The 
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results showed a decrease in EZH2 expression and a concomitant downregulation of 
H3K27me3 levels in the cells with increasing concentrations of DZNep (figure 7A). 
 
Figure 7A. Western blot showing progressive downregulation of H3K27me3 in lymphoma cell lines treated 
with gradually increasing DZNep concentrations. Figure adapted from Akpa C. A. et al., (180). 
To investigate whether DZNep has to capacity to reduce H3K27me3 level despite this protein 
being overexpressed in EZH2-mutated lymphoma cell lines, we treated 4 cell lines with DZNep. 
2 of these cell lines represent EZH2-mutated cell lines (WSU-DLCL-2 and Carnaval), and the 
other 2 representative of wild-type EZH2 cell lines (BL-2 and BLUE-1). Western blot with 
whole cell protein lysate from the cells was performed showing PARP cleavage, EZH2 and 
H3K27me3 expression. The results indicate that there is increased H3K27me3 in cell lines 
having the EZH2 Tyr646 mutation, however, DZNep decreases this histone trimethylation 
mark, promoting apoptotic death of the cells (figure 7B).  
 
Figure 7B. Decrease in H3K27me7 in EZH2-mutated cell lines treated with DZNep. Figure adapted from 
Akpa C. A. et al., (180). 
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3.5 DZNep suppresses the proliferation of lymphoma cells 
Considering that DZNep possesses a strong capacity to induce apoptosis in lymphoma cells, we 
considered looking into its effect on lymphoma cell proliferation. First, we analyzed the 
expression of proliferation-associated genes - proliferating cell nuclear antigen (PCNA) and 
cyclin dependent kinase 2 (CDK2) - in 7 cell lines including the generated DZNep-resistant 
clone and its control, in the presence and absence of DZNep pressure. The results displayed a 
decrease in the expression of these two proliferation markers in the DZNep-treated cell lines 
when compared to the untreated controls (figure 8A).  
 
Figure 8A. DZNep decreases the expression of the proliferation genes PCNA and CDK2 in lymphoma cell 
lines. Lymphoma cell lines were either untreated or treated with 5µM DZNep for 72 hours. Cells were harvested 
and RNA extracted from them. This was followed by cDNA synthesis and analysis of relative PCNA and CDK2 
gene expression by real-time RT-PCR. The untreated samples were used as reference while B2M was used as an 
endogenous control. 
Since the above analysis was made without exclusion of the dead and apoptotic cell population 
from the total cells used for RNA synthesis, we also used flow cytometry to confirm the effect 
of DZNep on proliferation. Using this method, the number of vital cells present in the culture 
was counted, while excluding the dead and apoptotic cells present under DZNep-treated and 
untreated conditions. The results showed a time-dependent decrease in the proliferation rate of 
the cell lines in presence of DZNep (figure 8B). At 72 hours, we could notice a clear decrease 
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in the number of vital cells present in the culture under DZNep pressure in comparison to the 
untreated cultures.  
 
Figure 8B. DZNep inhibits proliferation of lymphoma cell lines. We measured proliferation of EZH2-mutated 
(Carnaval and KARPAS-422) and EZH2 wild-type (BL-41, HT, BLUE-1, BLUE-1R10 and BLUE-1K10) cell 
lines either treated or untreated with 5 µM DZNep for 24, 48 and 72 hours. Figures for BL-41, KARPAS-422, HT, 
Carnaval and BLUE-1 were adapted from Akpa C. A. et al.,(180).  
 
3.6 Comparison of the apoptotic effect of DZNep and EPZ-6438 
We analyzed the efficacy of DZNep and EPZ-6432 - a direct EZH2 inhibitor currently tested 
in clinical trials (phase II) - in mediating apoptosis. Initially, 2 EZH2-mutant and 2 EZH2 wild-
type cell lines were treated with 5 µM of both DZNep and EPZ-6438 respectively. The results 
obtained following measurement of the number of apoptotic cells indicate that DZNep exhibited 
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no inclination towards causing apoptosis in either types of cell lines (figure 9A). The percentage 
of apoptosis caused by 5 µM EPZ-6438 however, was obviously lower in comparison to that 
measured in presence of 5 µM DZNep. Even the cell line classified as DZNep-resistant (HT) 
showed about 10% more apoptotic cells in comparison to EPZ-6438 under identical culture 
conditions. 
 
Figure 9A. Stronger apoptosis is measured within a short time after DZNep treatment in comparison with 
that observed after EPZ-6438 treatment. Each of the cell lines was treated for 72 hours with 5 µM DZNep and 
5 µM EPZ-6438 respectively. The percentage of apoptotic cells were measured afterwards by flow cytometry. 
Data is presented as mean plus SD from three independent measurements. Figure adapted from Akpa C. A. et 
al.,(180). 
 
Prolonged EPZ-6438 treatment of the same cell lines used in figure 9A (HT, BL-41, KARPAS-
422 and Carnaval) was performed based on a previous report (139). In this case, the cell lines 
were treated for up to 13 days with both 5 µM and 10 µM EPZ-6438 as described (180). We 
noticed (figure 9B) that the DZNep-sensitive EZH2-mutant and wild-type EZH2 cell lines 
exhibited an almost similar percentage of apoptosis after treatment with this drug even at 13 
days post-exposure. The concentration of the inhibitor used did not seem to make a huge 
difference as to the percentage of apoptosis measured. However, HT cell line, which is DZNep-
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resistant, exhibited a robust proportion of apoptotic cells, which was obvious after the third day 
following EPZ-6438-treatment.  
Figure 9B. EPZ-6438 causes apoptosis in both DZNep-sensitive and DZNep-resistant cell lines upon long-
term exposure. HT, BL-41, KARPAS-422 and Carnaval cell lines were administered 5 µM and 10 µM EPZ-6438 
for a duration of 13 days. The cells were split, apoptosis was measured, and culture medium was replaced every 
third to fourth day. The respective amounts of the inhibitor was replaced in the culture medium following medium 
change. The equivalent amount of DMSO was also replaced in the culture medium of the negative control (as this 
was the solvent for EPZ-6438). The percentage of apoptotic cells as determined by flow cytometry is shown as 
mean plus SD from 3 independent measurements. Figure adapted from Akpa C. A. et al.,(180). 
To investigate the apoptotic effect of EPZ-6438 on the generated DZNep-resistant clone, its 
corresponding control and the parent cell line from which it was generated (BLUE-1), a similar 
experiment to that performed in figure 9B was set up. This time, we treated the cell lines BLUE-
1, BLUE-1K10 and BLUE-1R10 with 10 µM EPZ-6438 for up to 13 days accordingly. We 
showed that BLUE-1 as well as the generated clone and corresponding control were resistant 




Figure 9C. The DZNep-resistant clone is also resistant to EPZ-6438. The DZNep-sensitive BLUE-1 cell line, 
the generated DZNep-resistant cell line BLUE-1R10 as well as its corresponding control BLUE-1K10 were treated 
with 10 µM EPZ-6438 for up to 13 days. The cells were split, apoptosis was measured, and the culture medium 
was replaced every third to fourth day. 10 µM EPZ-6438 was replaced in the culture medium following medium 
change. The controls received the same concentration of DMSO (10 µM). The above data is presented as mean 
plus SD from triplicate measurements. 
 
3.7 Characterization of the generated DZNep-resistant clone  
Because some cell lines are resistant to DZNep despite its strong apoptotic capacity, we aimed 
to probe the molecular mechanism behind this resistance and to detect biomarkers, which could 
be predictive of the therapeutic success of EZH2 inhibition with DZNep. To this end, we 
generated a DZNep resistant cell line as described in section 2.4 and characterized it alongside 
its corresponding control and the parent cell line BLUE-1.  
First, we determined that this clone and control actually derived from the parent BLUE-1 cell 
line. One way this was done was by checking for the expression of distinct B-cell surface 
markers CD19 and CD20 to confirm cell lineage identity. This was done by 
immunophenotyping (described in section 2.3). As expected, both cell lines expressed CD19 




Figure 10A. Flow cytometry histograms showing cell surface expression of CD19 and CD20 in BLUE-1, 
BLUE-1K10 and BLUE-1R10. The cells were stained with the respective fluorescent-labelled antibodies against 
CD19 and CD20. Using flow cytometry, the fluorescence intensity of cells expressing the CD markers was 
detected. The dashed red line shows the respective cell line of interest, the dashed black line shows the isotype / 
negative control, and the dashed green line highlights the positive control (U-2932 R1 cell line).  
In addition, we performed clonality studies to confirm the identity of the generated resistant 
clone and its control. This was done by checking the IGH gene rearrangement in the resistant 
clone, its corresponding control and cell line of origin. The results obtained showed that the 
IGH gene rearrangement for the three cell line clones (BLUE-1, BLUE-1R10 and BLUE-1K10) 




Figure 10B. BLUE-1, BLUE-1K10 and BLUE-1R10 exhibit identical B-cell clonality following multiplex 
PCR and accompanying GeneScan analysis of the resultant FR1 and FR2 sequences. FR1 sequences of the 
IGH gene for the three cell lines show monoallelic rearrangements (with one dominant blue peak) while FR2 
sequences show biallelic rearrangements (two dominant blue peaks) as determined by GeneScan analysis. Figure 
adapted from Akpa C. A. et al., manuscript in review (appendix C). 
Furthermore, the authenticity of the parent BLUE-1 cell line, the resistant clone and its control 
was verified and all three cell lines showed a short tandem repeat (STR) profile of a BLUE-1 
cell line. The results of the chromosome analysis (karyotyping) for the three cell lines was also 




Figure 10C. Karyotypes of BLUE-1, BLUE-1K10 and BLUE-1R10. The karyotype was written with the 
international nomenclature (ISCN) 2013.The analysis was performed in collaboration with the research group of 
Prof. Reiner Siebert. Figure adapted from Akpa C. A. et al., manuscript in review (appendix C). 
We further characterized the resistant clone by determining the doubling time in comparison to 
the corresponding control and the parent cell line. We showed that both BLUE-1K10 and 
BLUE-1R10 proliferate faster and have shorter doubling times than the parent cell line BLUE-




Figure 10D. BLUE-1, BLUE-1K10 and BLUE-1R10 proliferation rate analysis. The doubling time for BLUE-
1, BLUE-1R10 and BLUE-1K10 cell lines was determined using measurements of the number of vital cells at 0 
hours (beginning of incubation time) and at 48 hours (end of incubation time). The result is shown as mean plus 
SD from three measurements. ns means not significant. Figure adapted from Akpa C. A. et al., manuscript in 
review (appendix C).  
More so, we analyzed the response of the generated DZNep-resistant clone and its 
corresponding control to DZNep treatment. In comparison with BLUE-1R10, BLUE-1K10 
exhibited about 40% more apoptotic cells upon treatment of both cell lines for 72 hours with 5 
µM DZNep (figure 10E). In addition, Western blot analysis of total protein lysates derived from 
both cell lines treated with 2 µM and 5 µM DZNep for 72 hours showed an increased cleaved 





Figure 10E. BLUE-1K10 undergoes apoptosis when treated with DZNep while BLUE-1R10 is resistant to 
DZNep. Left: The fraction of apoptotic cells was determined following treatment of both cell lines for 72 hours 
with 5 µM DZNep. The controls were left untreated in culture. Flow cytometry was used for determination of the 
fraction of apoptotic cells. Data is presented as mean plus SD from three independent measurements. Right: 
Western blot showing the expression of cleaved PARP upon treatment of both cell lines with DZNep. GAPDH 
served as a loading control. Figure adapted from Akpa C. A. et al., manuscript in review (appendix C). 
3.8 Identification of biomarkers underlying the resistance of BLUE-1R10 
A microarray-based whole-genome copy number assay (OncoScan) was done to detect genomic 
changes such as copy number gains or losses and copy number neutral losses of heterozygosity 
in the cell lines BLUE-1K10, BLUE-1R10 and BLUE-1. The copy number alterations detected 
in the chromosomes are shown in figure 11A. As expected, all three cell lines harbored a 
deletion in 14qter which overlaps with the immunoglobulin heavy chain (IGH) locus which 
indicates a clonal rearrangement of these loci. A comparison of the copy number aberrations 





Figure 11A. Analysis of copy number alterations in the three BLUE-1 cell lines. In panel A are the log2 ratios 
for all three BLUE-1 samples depicted. Values centered around 0 indicate no aberrations whereas, an increased 
log2 ratio indicates a copy number gain and a decreased log2 ratio, a copy number loss. Of note, copy number 
neutral losses of heterozygosity (CNN-LOH) cannot be observed by log2 ratio. Panel B depicts the results of the 
chromosomal imbalance profiling for all three cell lines. The upper row shows the frequency of every alteration 
while the lower rows depict the CNA separately for all cell lines. Copy number gains are shown with blue bars, 
losses with red bars and CNN-LOH in orange bars. This picture clearly depicts that the majority of the CNA are 
shared between all BLUE-1 cell lines. The analysis was performed in collaboration with the research group of 







Table 7. Comparative copy number alterations (CNA) detected in BLUE-1, BLUE-1K10 and BLUE-1R10 
as identified by OncoScan analysis. 




Loss chr4:53960195-54283313 323.118 4 BLUE-1-R10 
Gain chr6:204908-28013410 27808.502 396 BLUE-1 
High copy 
gain 
chr6:86373374-87809402 1436.028 9 BLUE-1-R10 
Gain chr13:19084822-115103150 96018.328 968 BLUE-1 & BLUE-1K10* 
Gain chr16:8947035-11210415 2263.38 176 BLUE-1 & BLUE-1R10 
Gain chr16:11229588-23143876 11914.288 787 BLUE-1 & BLUE-1R10 
Gain chr16:23156450-90158005 67001.555 4049 BLUE-1 & BLUE-1R10 
Gain chr19:18306750-59093239 40786.489 1597 BLUE-1 
Gain chr19:247231-18101830 17854.599 866 BLUE-1 
Gain chr19:27754572-59093239 31338.667 1419 BLUE-1 & BLUE-1R10 
CN-LOH chr20:69093-11891608 11822.515 213 BLUE-1-R10 
CN-LOH indicates copy neutral loss of heterozygosity. *aberration is recognized as two events by the software. 
The above table was generated in collaboration with the research group of Prof. Reiner Siebert. Table was adapted 
from Akpa C. A. et al., manuscript in review (appendix C). 
Copy number variant analysis was also done on the WES data from BLUE-1R10 and BLUE-
1K10 as described (section 2.10). On chromosome 6, we detected a high copy number gain for 
the SNHG5, SMIM11P1, HTR1E and CGA genes (left of figure 11B). On chromosome 20, we 
detected a prominent gain in the copy number for the AHCY gene; this gain extending until the 




Figure 11B. Copy ratio plot (log2) of CNV regions in BLUE-1R10 when compared with BLUE-1K10. 
Individual genes are represented with the yellow bars while copy ratio values are represented with the gray dots. 
Copy number plots were generated in collaboration with the research group of Dr. Dieter Beule. The copy ratio 
plot for chromosome 20 was adapted from Akpa C. A. et al., manuscript in review (appendix C). 
3.9 Validation of the detected AHCY copy number gain  
3.9.1 Validation of AHCY copy number gain at the DNA level  
From the listed targets, AHCY seemed most promising for further validation since it is the direct 
target of DZNep. Validation was performed using different techniques. One technique we used 
was the TaqMan CNV assay. This was performed on genomic DNA from all 12 cell lines, 
including BLUE-1R10 and BLUE-1R12 and their corresponding controls. The results show an 
increase in the AHCY copy number in BLUE-1R10, with about two-fold increase in BLUE-
1R12 (figure 12A). We did not observe a profound AHCY copy number gain in the other 





Figure 12A. Copy number variation profile of the lymphoma cell lines. The AHCY TaqMan CNV assay (ID: 
Hs02422126_cn) was utilized for the analysis of genomic DNA derived from the respective cell lines. CopyCaller 
software was used to perform data analysis. A commercially available human genomic DNA control 
(ThermoFisher Scientific, Germany) was used to calibrate the assay. 
Having shown the profound increase in the copy number of AHCY in the DZNep-resistant 
clone, we sought to trace the time point at which the resistant clone evolved with this copy 
number aberration. For this purpose, we performed the TaqMan CNV assay on extracted DNA 
from the cell lines acquired at different points during the evolution of the clone. We demonstrate 
a clear gain in the AHCY copy number starting from BLUE-1R6, this gain increasing 
progressively during subsequent months. During the month when DZNep pressure was 
withdrawn from the cells (from BLUE-1R9 to BLUE-1R10), we observed a doubling of the 




Figure 12B. AHCY copy number evolution in the DZNep-resistant clone. The AHCY TaqMan CNV assay (ID: 
Hs02422126_cn) was used for the analysis of genomic DNA derived from the respective cell lines. The CopyCaller 
software was used for copy number analysis. A primary tonsil sample (TRR_098) was used as a reference sample 
for the assay. Data was adapted from Akpa C. A. et al., manuscript in review (appendix C). 
We repeated this experiment with a different AHCY TaqMan CNV assay to ensure that we 
were really detecting the gene of interest. This assay (ID: Hs02512802_cn) was designed to 
detect a region of AHCY overlapping intron 3 and exon 3, in contrast to the former assay which 
recognizes a region of AHCY overlapping intron 7 and exon 8. The results obtained (figure 12C) 




Figure 12C. AHCY copy number evolution in the DZNep-resistant clone (use of a different assay). The 
AHCY TaqMan CNV assay (ID: Hs02512802_cn) was used to interrogate genomic DNA from the individual cell 
lines. Copy number analysis was done using the CopyCaller software. DNA from a primary tonsil sample 
(TRR_098) served as a reference for the assay. 
We also performed CNV analysis using generated DNA methylation data (refer to section 2.11). 
The result of the analysis showed an increased AHCY copy number in BLUE-1R10, which was 










Figure 12D. AHCY gain depicted using CNV plots derived from global DNA methylation data. Log2 copy 
number ratio is shown on the y-axis. AHCY copy number gain in BLUE-1R10 is shown in the area within the red 
circle. CNV analysis of the methylation data was performed in collaboration with the research group of Prof. David 
Capper. Figure adapted from Akpa C. A. et al., manuscript in review (appendix C). 
Upon manual analysis of the OncoScan CNV assay (AHCY genomic region) that was initially 
performed in section 3.8, the result (figure 12E) confirmed the high copy number gain of AHCY 
in BLUE-1R10, not visible in other BLUE-1 derivatives. It is worthy to note that due to the 
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filtering criteria used for detection of CNA (see section 2.13), this alteration was not picked up 
in the initial analysis due to the small size of this genomic region and low probe coverage. 
 
Figure 12E. Validation of the AHCY CNV in BLUE-1R10 using OncoScan CNV assay. OncoScan CNV assay 
results showing on chromosome 20, the log2 ratios for BLUE-1, BLUE-1K10 and BLUE-1R10. The region 
highlighted with a red arrow shows the AHCY copy number gain. OncoScan CNV analysis was done in 
collaboration with the research group of Prof. Reiner Siebert. Figure adapted from Akpa C. A. et al., manuscript 
in review (appendix C). 
3.9.2 Validation of AHCY copy number gain at the chromosomal level 
We performed FISH analysis using AHCY-specific probes to detect AHCY amplification in the 
resistant clone at the chromosomal level. The result (figure 12F) displayed cluster-type 
amplification of AHCY appearing as homogeneously stained regions in BLUE-1R10 cells in 
comparison with BLUE-1K10 cells. This amplification, corroborating the results of the CNV 




Figure 12F. Validation of AHCY copy number gain on the chromosomal level by FISH analysis. The yellow 
arrows show AHCY amplification (in pink clusters). Chromosome 20 centromere is shown in green dots. The blue 
color (DAPI stain) highlights the cell nucleus. FISH analysis was performed in collaboration with Dr. Dido Lenze. 
Figure adapted from Akpa C. A. et al., manuscript in review (appendix C). 
3.9.3 Validation of AHCY copy number gain at the transcriptional level 
To validate the expression of AHCY, real-time RT-PCR was performed on RNA from the cell 
lines using the AHCY TaqMan gene expression assay kit. Consistent with the preceding results, 
AHCY was overexpressed in the resistant clone but not the corresponding controls. Moreover, 
the expression of AHCY in BLUE-1R12 was about 2-times greater than the expression of 
AHCY in BLUE-1R10. Amplification of AHCY was not detected in the other 12 lymphoma 
cell lines used in this work (figure 12G). 
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Figure 12G. Expression of AHCY at the transcriptional level. Real-time RT-PCR was performed on RNA 
extracted from the respective cell lines. The y-axis indicates the relative gene expression. AHCY TaqMan gene 
expression assay was used for mRNA quantification. The data for BLUE-1, BLUE-1K10, BLUE-1K12, BLUE-
1R10 and BLUE-1R12 were adapted from Akpa C. A. et al., manuscript in review (appendix C). 
3.9.4 Validation of AHCY copy number gain at the protein level  
AHCY protein expression in the cell lines was investigated using IHC and Western blot. IHC 
results revealed AHCY overexpression in BLUE-1R12 in relation with BLUE-1K12 and 
BLUE-1 (figure 12H). Upon treatment of BLUE-1R12 with DZNep, the expression of AHCY 
protein seemed even more in comparison to BLUE-1R12 without DZNep pressure. 
Furthermore, BLUE-1R12 showed a more cytoplasmic AHCY immunostaining in comparison 
to BLUE-1K12, where there seemed to be a more nuclear AHCY immunostaining of the cells. 
Other lymphoma cell lines analyzed for their AHCY expression did not show a strong AHCY 
staining like that observed in the resistant clone (BLUE-1R12).  
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Figure 12H. IHC results of lymphoma cell lines. Anti-AHCY antibody was used to stain FFPE sections of the 
individual cell lines. IHC results for BLUE-1, BLUE-1K12 and BLUE-1R12 were adapted from Akpa C. A. et al., 
manuscript in review (appendix C). 
Western blot was also performed to check for overexpression of AHCY at the protein level 
using whole cell protein lysates derived from all 12 lymphoma cell lines, as well as the resistant 
clone and their respective controls. The protein expression profile revealed AHCY 
overexpression in BLUE-1R10, with a further increase in BLUE-1R12. The other lymphoma 
cell lines only showed a basal expression of AHCY protein, similar to that seen in a HeLa cell 
line used as a positive control for AHCY in this experiment (figure 12I). 
 
Figure 12I. AHCY is overexpressed in the DZNep-resistant clone. Total cell protein lysate extracted from the 
respective cell lines were analyzed with Western blot. Protein lysate from a HeLa cell line was used as a positive 
control for AHCY. Histone 3 served as the loading control. The Western blot figure for the cell lines BLUE-1, 
BLUE-1K10, BLUE-1R10, BLUE-1K12 and BLUE-1R12 was adapted from Akpa C. A. et al., manuscript in 
review (appendix C). 
As mentioned in the IHC results of figure 12H, there seemed to be a more cytoplasmic AHCY 
immunostaining in BLUE-1R12 in comparison to BLUE-1K12, which appeared to show a more 
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nuclear AHCY immunostaining. This led to the speculation that AHCY may display different 
subcellular localizations in presence and absence of DZNep. To clarify if it could be the case 
that perhaps, treatment of cell lines with DZNep causes the drift of AHCY from the nucleus to 
the cytoplasmic cellular compartment, we separated the nuclear and cytoplasmic fractions of 
the resistant clone BLUE-1R10, its control BLUE-1K10 and another lymphoma cell line BL-2. 
We then performed a Western blot analysis to show the cytoplasmic distribution of AHCY 
before and after DZNep treatment. We observed in all cases that AHCY was more in the 
cytoplasm under conditions of DZNep pressure and without DZNep pressure (figure 12J). 
 
Figure 12J. AHCY is mainly distributed in the cytoplasm of the cell irrespective of DZNep pressure. Whole 
cell protein lysates as well as protein lysates from the cytoplasmic and nuclear fractions of the respective cell lines, 
either untreated or treated with DZNep were used for the Western blot. GAPDH served as a positive control for 
the cytoplasmic fraction and Histone 3 served as a positive control for the nuclear cell fraction. The blots were 
stripped and incubated with anti-AHCY primary antibody.  
 
3.9.5 Validation of AHCY copy number in primary patient samples  
To validate AHCY copy number variation in patient samples, we analyzed a diverse group of 
11 primary lymphoma samples made up of BL, DLBCL, follicular lymphoma, PMBL and 
anaplastic large cell lymphoma. Genomic DNA was isolated from the tissue sections and 
subjected to the AHCY TaqMan CNV assay (ID: Hs02422126_cn). The AHCY copy number as 
determined by the CopyCaller software was 2 copies for all except one of the samples with a 




Figure 12K. Validation of AHCY CNV in primary patient samples. The AHCY TaqMan CNV assay (assay 
ID: Hs02422126_cn) was used for the copy number analysis, with a human tonsil sample (TRR_098) serving as a 
reference for the assay. The CopyCaller software was used for data analysis. Highlighted in red is the sample 
predicted by the software to have one copy of the AHCY gene deleted. Data adapted from Akpa C. A. et al., 
manuscript in review (appendix C). 
3.10 Effect of DZNep on AHCY expression 
Although DZNep is a known AHCY inhibitor, we sought to investigate the effect of DZNep on 
AHCY expression at the RNA level. To this end, we treated cell lines with 5 µM DZNep for 
72 hours and measured the AHCY RNA expression in the cells using real-time RT-PCR. We 
used two DZNep-resistant cell lines, BLUE-1R10 and HT, and 3 DZNep sensitive cell lines, 
BL-41, BLUE-1 and BLUE-1K10. Our results showed a decrease in expression of AHCY upon 




Figure 13: Expression of AHCY in DZNep-resistant and DZNep-sensitive cells upon treatment with DZNep. 
(A) 2x105 cells from each of the cell lines were cultured in 6 well plates, and either untreated or treated with 5 µM 
DZNep for 72 hours. Cells were harvested, RNA extracted and real-time RT-PCR performed to determine AHCY 
expression. The AHCY TaqMan gene expression assay was used to analyze AHCY expression, with B2M serving 
as an endogenous control. The y-axis represents the relative AHCY gene expression (B) Due to the very high 
AHCY expression in BLUE-1R10, we excluded it from the analysis to take a closer look at the AHCY expression 
(in presence and absence of DZNep) for the DZNep-sensitive cell lines (BL-41, BLUE-1, BLUE-1K10) and the 
DZNep-resistant cell line (HT).  
3.11 Metabolomics 
We analyzed the concentrations of selected metabolites of methionine (SAH, adenine and 
adenosine) when lymphoma cells are treated with DZNep. We investigated the cell lines BLUE-
1, BLUE-1K10, BLUE-1R10, BLUE-1K12 and BLUE-1R12 as described in section 2.13. We 
observed that the three metabolites were distributed in a similar manner in BLUE-1, BLUE-
1K10 and BLUE-1K12. In BLUE-1R10 treated with DZNep, we clearly observed an increase 
in SAH. However, in the resistant clone without DZNep pressure (BLUE-1R12), there was a 





























































Figure 14. Quantification of metabolites of s-adenosylmethionine (SAM). SAH: S-adenosylhomocysteine. 
Metabolomics analysis was performed in collaboration with the research group of Prof. Peter J. Oefner. Data of 
BLUE-1, BLUE-1K12 and BLUE-1R12 was adapted from Akpa C. A. et al., manuscript in review (appendix C). 
3.12. Global DNA methylation profile of BLUE-1, BLUE-1K10 and BLUE-1R10 
We looked into the global DNA methylation status of the lymphoma cell lines BLUE-1, BLUE-
1K10 and BLUE-1R10, with and without DZNep pressure. We first analyzed this using a 
colorimetric approach - the MethylFlash Global DNA methylation (5-mC) ELISA Easy Kit 
assay. This assay was performed two independent times on similar samples. We noticed from 
the results of the first experiment (figure 15A (I)), a higher methylation level (percentage of 5-
methylcytocine (5-mC)) for all the cell lines analyzed in comparison to the results of the 
replicate analysis (figure 15A (II)). In the latter experiment, we observed a much lower 
percentage of 5-mC, with varying levels in all the samples analyzed. Due to the inconsistencies 
and non-reproducibility encountered with this colorimetric assay, we applied an array-based 




Figure 15A. Global DNA methylation status of BLUE-1, BLUE-1K10 and BLUE-1R10, with and without 
DZNep pressure. ELISA-based colorimetric determination of the global DNA methylation profile of the 
respective cell lines. (I) First experiment performed on the respective cell line DNA samples. DZNep treated cells 
received 5 µM DZNep for 72 hours. (II) Replication of the first experiment. 
We utilized the Infinium MethylationEPIC BeadChip Kit, a microarray-based method, capable 
of examining thousands of methylation sites throughout the genome with high resolution (200). 
We adopted this method, with the purpose of providing a deeper and more concise 
understanding of the genome-wide methylation pattern of individual genes.  
Hierarchical clustering as well as principal component analysis (PCA) was performed on the 
25000 most variant probes (methylation sites) to show the similarities between the methylation 
data of the cell lines (BLUE-1, BLUE-1K10, BLUE-1K10 treated with DZNep, BLUE-1R10 
and BLUE-1R10 treated with DZNep) and their replicates. We also compared the methylation 
data obtained from the cell lines with those of primary tumor samples. From the clustering 
results and PCA (figures 15B and 15C respectively), we noticed similarity in the methylation 
patterns of the DZNep-treated cell lines, as well as more clustering together of untreated cell 
lines. Comparing the cell lines’ methylation data with those of primary tumor samples, we 
observed that the methylation patterns of each type of primary sample (lymphoma and 
plasmacytoma) are much similar to each other. The cell lines, even with the intra-group 




Figure 15B. Dendrogram shows hierarchical clustering results of the methylation dataset of the respective 
cell lines, plasmacytoma and lymphoma patient samples. Rep1 indicates the first set of samples while Rep2 
denotes the replicate sample used for the data analysis. Included are the 13 primary lymphoma and 8 primary 




Figure 15C. Depicted are the first two dimensions of a PCA of the 25000 most variably methylated probes 
of cell lines and primary lymphoma patient samples (methylation class lymphoma and methylation class 
plasmacytoma). Methylation data was analyzed in collaboration with the research group of Prof. David Capper. 
Further analysis of the methylation data was done to determine genes differentially methylated 
between BLUE-1K10 and BLUE-1R10 (group 1) as well as between 2 DZNep-sensitive 
(Carnaval and BL-41) and 2 DZNep-resistant (HT and CA-46) cell lines (group 2). A Venn 
diagram showing the overlap between genes which were differentially methylated in both 
groups was created using the Venny 2.1 software (201). We identified around 5036 overlapping 
genes comprising about 24% of the identified differentially methylated targets between the two 




Figure 15D. Differentially methylated targets in BLUE-1K10 versus BLUE-1R10 and DZNep-sensitive 
(Carnaval and BL-41) versus DZNep-resistant (HT and CA-46) cell lines. Differentially methylated probes 
were defined by having an adjusted p-value of below 0.01. 
To probe the effect of DZNep on the global methylation profile of BLUE-1K10 and BLUE-
1R10, we investigated differentially methylated genes in these cell lines before and upon 
treatment with 5 µM DZNep. Upon examination of BLUE-1K10 in presence and absence of 
DZNep pressure (group 3), we identified 21359 differentially methylated targets (figure 15E). 
Analysis of the DZNep-resistant clone BLUE-1R10 yielded no differentially methylated genes 
under DZNep-treated and untreated conditions based on the criteria for defining differentially 
methylated probes (adjusted p-value < 0.01).  
 
Figure 15E. Differentially methylated targets in BLUE-1K10 versus BLUE-1K10 + DZNep. There were no 
differentially methylated targets detected when comparing BLUE-1R10 under untreated and DZNep-treated 
conditions. Differentially methylated probes were defined by having an adjusted p-value of below 0.01. 
Sequel to this, a pathway analysis to determine differentially methylated genes involved in the 
apoptosis signaling pathway was done, focusing the overlapping genes from groups 1, 2 and 3. 
Out of 1942 pathway hits, 38 differentially methylated genes were identified using the 
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PANTHER classification system (202) as being involved in the apoptosis signaling pathway 
(table 8).  
Table 8. List of differentially methylated genes involved in the apoptosis signaling pathway, identical to 
group 1 (BLUE-1K10 versus BLUE-1R10), group 2 (DZNep-sensitive versus DZNep-resistant cell lines) and 
group 3 (BLUE-1K10 versus BLUE-1K10 + DZNep).  
Gene Name Gene Symbol 
1 Protein kinase C eta type PRKCH 
2 Mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4 
3 TNF receptor-associated factor 2 TRAF2 
4 Mitogen-activated protein kinase kinase kinase kinase 2 MAP4K2 
5 DNA replication licensing factor MCM5 MCM5 
6 Proto-oncogene c-Fos FOS 
7 Protein kinase C delta type SDK1 
8 Heat shock 70 kDa protein 6 HSPA6 
9 BCcl-2-related ovarian killer protein BOK 
10 Cyclic AMP-dependent transcription factor ATF-7 ATF7 
11 Mitogen-activated protein kinase 1 MAPK1 
12 Mitogen-activated protein kinase kinase kinase kinase 5 MAP4K5 
13 Protein kinase C epsilon type PRKCE 
14 Transcription factor p65 RELA 
15 Protein kinase C theta type PRKCQ 
16 Cyclic AMP-dependent transcription factor ATF-6 beta ATF6B 
17 Mitogen-activated protein kinase kinase kinase kinase 3 MAP4K3 
18 CASP8 and FADD-like apoptosis regulator CFLAR 
19 Caspase-3 CASP3 
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20 Cyclic AMP-dependent transcription factor ATF-6 alpha ATF6 
21 Apoptosis regulator Bcl-2 BCL2 
22 Eukaryotic translation initiation factor 2 subunit 1 EIF2S1 
23 MAP kinase-activating death domain protein MADD 
24 Interferon-inducible double-stranded RNA-dependent protein kinase activator A PRKRA 
25 RAC-gamma serine/threonine-protein kinase AKT3 
26 Bcl-2-like protein 2 BCL2L2 
27 Cyclic AMP-dependent transcription factor ATF-3 ATF3 
28 RAC-alpha serine/threonine-protein kinase AKT1 
29 cAMP-responsive element modulator CREM 
30 Mitogen-activated protein kinase kinase kinase 14 MAP3K14 
31 Protein kinase C alpha type PRKCA 
32 Tumor necrosis factor receptor superfamily member 1B TNFRSF1B 
33 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD 
34 Caspase-10 CASP10 
35 Tumor necrosis factor receptor type 1-associated DEATH domain protein TRADD 
36 Inhibitor of nuclear factor kappa-B kinase subunit beta IKBKB 
37 Death domain-associated protein 6 DAXX 
38 RAC-beta serine/threonine-protein kinase AKT2 
The list of differentially methylated targets from group 1, group 2 and group 3 is shown in the 
supplementary file S1. 
3.13. Functional validation of AHCY copy number gain (AHCY knockdown assays) 
To validate the functional relevance of increased AHCY gene expression observed in BLUE-
1R10, we sought to knock down AHCY in this resistant clone and to check if it would regain 
sensitivity to apoptosis upon treatment with DZNep. We first performed an assay to establish 
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optimal conditions for the transfection of BLUE-1R10 cell line. Following the assay set-up 
shown in table 9A, and using the method described in section 2.15.1, we tested various 
programs designed for transfection of BLUE-1R10 with the Nucleofector 2b Device. 
Table 9A: Plate set-up for the experiment to determine the optimal conditions for transfection of BLUE-
1R10. 
Sample Cell culture medium pmaxGFP; 0.5 µg/µl Program 
Sample  01 [NTC] 4 ml (6-well plate) - Q-06 
Sample  02 [+ GFP] 4 ml (6-well plate) + 4 µl GFP D-28 
Sample  03 [+ GFP] 4 ml (6-well plate) + 4 µl GFP O-07 
Sample  04 [+ GFP] 4 ml (6-well plate) + 4 µl GFP O-06 
Sample  05 [+ GFP] 4 ml (6-well plate) + 4 µl GFP D-23 
Sample  06 [+ GFP] 4 ml (6-well plate) + 4 µl GFP Q-06 
NTC means no template control. GFP: Green fluorescent protein 
The ‘test’ transfection was done using green fluorescent protein (pmaxGFP) vector (Lonza 
Group AG, Germany). At the end of transfection (48 hours), the lowest number of apoptotic 
cells and the highest percentage of GFP positive cells were obtained using the program D-23 
(figure 16A and table 9B). This program was then utilized for subsequent experiments involving 
the transfection of BLUE-1R10 with the electroporation technique. 
 
Figure 16A. Flow cytometry gating to determine the percentage of vital and GFP-positive cells. BLUE-1R10 
was transfected with pmaxGFP vector for 48 hours. The cells were counted and Annexin V (Ann V) - stained 
following transfection. The Ann V- stained cells indicate the apoptotic cells. The fluorescence intensity of GFP 
(percentage of GFP-positive cells) was measured using flow cytometry in the FL1 channel while that of Ann V 
(Ann V-positive cells) was measured in the FL-4 channel. 
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Table 9B: Table showing the number of vital cells and GFP-positive cells present in the culture upon 
transfection of BLUE-1R10 with GFP vector using various electroporation programs. 
Sample Total cell count (x 105) / ml  GFP - positive cells (%) GFP + Ann V -positive cells (%) Ann V - positive cells (%) 
Sample 01 [Q-06/NTC] 7.7 - - 44.0 
Sample 02 [D-28/GFP] 21.4 83.8 4.0 2.8 
Sample 03 [O-07/GFP] 20 66.5 3.1 6.6 
Sample 04 [O-06/GFP] 23.1 55.6 2.9 5.3 
Sample 05 [D-23/GFP] 25.0 85.2 3.9 2.4 
Sample 06 [Q-06/GFP] 8.8 35.7 7.5 42.6 
NTC means no template control. 
After determining the best conditions to use for transfection, we utilized 200 pmol/µl of both 
Mission AHCY esiRNA (human) and an ON-TARGETplus Non-targeting negative control 
pool for the transfection of BLUE-1R10. The percentage of apoptotic cells was determined 48 
hours later using flow cytometry and the results shown in table 9C. We noticed that the sample 
transfected with AHCY esiRNA (without DZNep treatment) had a similar number of vital cells 
when compared with the no template control. Upon treatment with 5 µM DZNep, the 
percentage of apoptotic cells (Ann V / propidium iodide (PI)-positive cells) measured was 
greater in comparison to the AHCY-transfected cells without DZNep treatment. This was also 
the case for the no template control treated with DZNep as well as the non-target controls. 
Table 9C: Flow cytometry read-out showing the percentage of vital cells and apoptotic cells present in the 
culture upon transfection of BLUE-1R10 with AHCY esiRNA. 
Sample Total cell count (x105) / ml  Vital cell count (x105) / ml  Ann V/PI-positive cells (%) 
Sample 01 [NTC] 7.7 6.0 22.1 
Sample 02 [esiRNA_AHCY] 7.1 5.1 29.2 
Sample 03 [esiRNA_AHCY + DZNep] 4.3 1.1 74.7 
Sample 04 [NTC + DZNep] 3.1 0.3 92.0 
Sample 05 [non-target_siRNA] 4.5 1.7 61.4 
Sample 06 [non-target_siRNA + DZNep] 5.0 0.8 83.7 
NTC means no template control. 
To check for transfection efficiency of the samples, Western blot using whole cell protein lysate 
from the cultured cells (in table 9C) was performed and antibodies detecting cleaved PARP, 
AHCY and Histone 3, were used to show expression of respective proteins (figure 16B). Our 
results showed that in comparison with the no template control (sample 01), the expression of 




Figure 16B. Western blot showing the transfection efficiency of BLUE-1R10 with AHCY esiRNA (using 
non-target negative control siRNA). Whole cell protein lysate of the samples from table 9C showing AHCY and 
cleaved PARP protein expression in the respective cells. Histone 3 served as a loading control. 
To check for reproducibility of the obtained result, the experiment was repeated. This time, we 
used an ON-TARGETplus human GAPDH control pool (ThermoFisher Scientific/Dharmacon, 
Germany) as a negative control rather than the non-targeting control pool, since we were unsure 
of its specificity. We also adjusted the duration of transfection (harvesting the cells 48 hours 
and 72 hours post-transfection) to check for the optimal time point for AHCY knockdown. The 
percentage of apoptotic cells and vital cells counted following transfection are shown in table 
9D. 
Table 9D: Flow cytometry results showing the percentage of vital cells and apoptotic cells present in the 
culture upon transfection of BLUE-1R10 with AHCY esiRNA. 
 Sample Total cell count (x105) / ml Vital cell count (x105) / ml Ann V/PI-positive cells (%) 
Sample 01 [NTC_48h] 
4.5 3.1 32.4 
Sample 02 [NTC + DZNep_48h] 3.9 1.8 53.3 
Sample 03 [esiRNA_AHCY_48h] 11.5 10.0 13.5 
Sample 04 [esiRNA_AHCY + DZNep_48h] 7.3 4.4 39.7 
Sample 05 [esiRNA_AHCY_72h] 21.4 19.9 7.3 
Sample 06 [esiRNA_AHCY + DZNep_72h] 6.8 4.8 30.3 
Sample 07 [siRNA_GAPDH_48h] 
5.3 4.1 21.3 
Sample 08 [siRNA_GAPDH + DZNep_48h] 4.2 2.0 51.8 
Sample  09 [Unpulsed] 13.6 12.4 9.2 
Sample 10 [Unpulsed + DZNep_48h] 
9.4 7.4 21.1 
NTC means no template control and siRNA targeting GAPDH was used as a negative control. 
Subsequent validation of the transfection efficiency of the cells using Western blot was done 
using whole cell protein lysate from the samples. Our results showed no obvious change in the 
level of AHCY expression in all the samples. However, samples 07 and 08 transfected with 
GAPDH siRNA showed a somewhat lower level of GAPDH expression in comparison with 




Figure 16C.Western blot showing the transfection efficiency of BLUE-1R10 transfected with AHCY esiRNA 
(using GAPDH negative control siRNA). Whole cell protein lysate from the samples of table 9D showing cleaved 
PARP, AHCY and GAPDH expression in the respective cells. Histone 3 served as a loading control. 
Since AHCY is overexpressed in BLUE-1R10, we adjusted the concentration of the esiRNA 
used (using 2 fold more than that previously applied) for transfection. The concentration of the 
AHCY esiRNA used this time was increased to 400 pmol/µl, and the transfection performed as 
already described for 48 hours. Upon analysis of the transfection efficiency of the cells using 
Western blot, no significant downregulation of AHCY was observed in the cells at the protein 
level (figure 16D). 
 
Figure 16D. Western blot showing the transfection efficiency of BLUE-1R10 transfected with AHCY 
esiRNA (varying the esiRNA concentration). Cells were cultured in 6-well plates at a seeding density of 5x106 
cells/ml. Electroporation of the transfected cells were carried out using 200 pmol/µl AHCY esiRNA and 400 
pmol/µl AHCY esiRNA. Transfection as well as DZNep treatment of both the samples and controls with 5 µM 
DZNep was done for a duration of 48 hours. Cells were harvested and counted afterwards using flow cytometry. 
Protein lysate was prepared from the cells of each sample and Western blot made to determine the efficiency of 
transfection. The blot was incubated with antibodies for cleaved PARP, AHCY and Histone 3. Histone 3 served 
as a loading control.  
The preceding result led to the presumption that AHCY is downregulated at an earlier time 
point than 48 hours. We thus reduced the transfection time to 16 and 24 hours. Western blot of 
the transfected samples was made and the expression of AHCY protein determined. In both 
cases, the results showed a poor AHCY knockdown efficiency (figure 16E). The siRNA 
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targeting GAPDH however, showed a good transfection efficiency, with GAPDH knocked 
down in BLUE-1R10 at both 16 hours and 24 hours after transfection.  
 
Figure 16E. Western blot showing the transfection efficiency of BLUE-1R10 transfected with AHCY 
esiRNA (varying the time of transfection). Cells were cultured in 6-well plates at a seeding density of 5x106 
cells/ml. Electroporation of the transfected cells were carried out using 200 pmol/µl AHCY esiRNA. Transfection 
using 200 pmol/µl GAPDH negative control siRNA and the Non-target negative control pool siRNA were 
performed as controls in parallel. Transfection was performed for 16 hours as well as 24 hours, after which the 
cells were harvested and counted. 3 x 106 cells were lysed and total protein lysate prepared from the cells of each 
sample. Western blot to examine the level of AHCY and GAPDH expression after transfection was performed 
with Histone 3 serving as a loading control for the experiment. 
Having given several attempts to knockdown AHCY in the resistant BLUE-1R10 cell line 
without success, we hypothesized that AHCY expression in BLUE-1R10 may be so high that 
large concentrations of AHCY esiRNA would not be able to reduce it to an extent observable 
at the protein level using the Western blot assay. To check if this was the case, we examined 
the expression of AHCY at the RNA level following transfection with the AHCY esiRNA. 
Cells were transfected once again according to the set-up in table 9E.  
Table 9E. Plate set-up for the transfection of BLUE-1R10 with esiRNA targeting AHCY (validation of 
transfection efficiency at the RNA level). 
Sample Medium  esiRNA AHCY Program Time 
Sample 01 [NTC]  4 ml (6-well plate) - D-23 24 hours 
Sample 02 4 ml (6-well plate) + 10 µl AHCY esiRNA (200 pmol/µl) D-23 24 hours 
Sample 03 4 ml (6-well plate) + 20 µl AHCY esiRNA (400 pmol/µl) D-23 24 hours 
Sample 04  4 ml (6-well plate) + 4 µl non-target siRNA (200 pmol/µl) D-23 24 hours 
Sample 05 [NTC]  4 ml (6-well plate) - D-23 48 hours 
Sample 06 4 ml (6-well plate) + 10 µl AHCY esiRNA (200 pmol/µl) D-23 
48 hours 
Sample 07 4 ml (6-well plate) + 20 µl AHCY esiRNA (400 pmol/µl) D-23 
48 hours 
Sample 08  4 ml (6-well plate) + 4 µl non-target siRNA (200 pmol/µl) D-23 
48 hours 
NTC means no template control. The transfection times were 24 hours and 48 hours respectively, with 200 pmol/µl 
and 400 pmol/µl of the esiRNA targeting AHCY. The non-target control pool was used as a negative control for 
the transfection.  
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At the end of transfection, cells were harvested and the number of vital cells analyzed using 
flow cytometry. All transfected cell cultures had an average percentage of apoptotic cells less 
than 15%. RNA was isolated from the cells of each sample and subjected to real-time RT-PCR 
analysis to determine AHCY gene expression. Our results confirmed that there was a decrease 
in the expression of AHCY in the cells following knockdown with increasing concentrations of 
the AHCY esiRNA at 24 hours (figure 16F). At 48 hours post-transfection this decrease was 
even more in the AHCY esiRNA-transfected cells. Despite the high concentration of AHCY 
esiRNA (400 pmol/µl) used for transfection of BLUE-1R10, the expression level of AHCY in 
a basic lymphoma cell line (BLUE-1) was not reached after knockdown. This explains why 
decreased AHCY expression was not evident in the cells at the protein level by Western blot. 
 
Figure 16F: RNA expression of AHCY in BLUE-1R10 following transfection with 200 pmol/µl and 400 
pmol/µl AHCY esiRNA. 5x106 cells of BLUE-1R10 were cultured in 6-well plates and electroporated to deliver 
the respective siRNAs into the cells. Cells were transfected for both 24 and 48 hours after which they were 
harvested and RNA extracted. The samples (from table 9E) were subjected to real-time RT-PCR quantitation to 
determine AHCY gene expression using the AHCY TaqMan gene expression assay. The y-axis shows the relative 
AHCY gene expression. TaqMan B2M gene expression assay served as an endogenous control.  
3.14. Functional validation of AHCY copy number gain (AHCY overexpression assays) 
We worked on overexpressing AHCY in BLUE-1K10 as well as in other DZNep-sensitive cell 
lines. The goal was to investigate whether these AHCY-overexpressed DZNep-sensitive cell 
lines would become DZNep resistant when treated with the drug. To achieve this, 3 DZNep 
sensitive lymphoma cell lines, BLUE-1K10, BL-41 and BL-2 as well as the DZNep-sensitive 
osteosarcoma cell line U-2-OS, were transfected with an AHCY expression plasmid and a 
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negative control plasmid as described in section 2.15. Transfection of the cell lines was 
performed using lipofection and confirmation of transfection efficiency was done using 
Western blot.  
The results show poor transfection efficiency of the lymphoma cell lines, as the protein 
expression of AHCY in the AHCY plasmid-transfected cells was similar in relation to the 
negative control and the untransfected cell lines (left of figure 17A). Transfection of the U-2-
OS cell line was however successful, with AHCY overexpressed relative to the negative control 
(right of figure 17A). 
 
Figure 17A. Western blot showing the transfection efficiency of DZNep-sensitive lymphoma cell lines (left) 
and an Osteosarcoma cell line (right), transfected with AHCY expression plasmid and negative control 
plasmid. Whole cell protein lysate from the transfected cells were used for Western blot. Beta-actin was used as 
a loading control. AHCY overexpression was performed in collaboration with the research group of Prof. Claus 
Scheidereit.  
Since AHCY overexpression was successful in U-2-OS, we performed down-stream assays 
with this cell line. The AHCY-overexpressed U-2-OS cells, the negative control-transfected U-
2-OS cells, as well as the untransfected U-2-OS cells were either untreated or treated with 5 
µM DZNep for 72 hours. The percentage of both vital and apoptotic cells was determined 
afterwards by flow cytometry. Data from the negative control-transfected cells was unavailable 
due to death of both the DZNep-treated and untreated cells in culture. Results of the 
untransfected U-2-OS cells showed a high percentage of apoptotic cells following DZNep 
treatment in comparison to the untreated control (a difference of about 40%) (left of figure 
17B). The AHCY-overexpressed U-2-OS cells treated with DZNep however, displayed a 
reduced percentage of apoptotic cells relative to its untreated control (a difference of about 
15%). Confirmation of AHCY overexpression and apoptosis induction by DZNep at the protein 
level was demonstrated using Western blot. The Western blot picture illustrates that in the 
untransfected cells, apoptosis was higher following DZNep treatment (as indicated by an 
increased expression of cleaved PARP), while in the AHCY-overexpressed cells, apoptosis was 




Figure 17B. AHCY-overexpressed U-2-OS cell line tends to be resistant to apoptosis upon DZNep treatment. 
Left: The adherent U-2-OS cell lines were cultured at a seeding density of 1x105 cells/ml for 24 hours without 
DZNep treatment to allow attachment of the cells to the surface of the culture vessel. Subsequently, 5 µM DZNep 
was administered to the cells treated with DZNep. The controls were left untreated. After a duration of 72 hours, 
the cells were trypsinized to release them from the surface of the culture plate. The resulting cells were counted, 
and the percentage of apoptotic cells determined with flow cytometry. Right: Samples from figure 17B (left) were 
used for the preparation of protein lysate with which Western blot was performed to show AHCY and cleaved 
PARP expression. Histone 3 (H3) served as a loading control.  
3.15. AHCY alterations in other DZNep-resistant cell lines 
From an available cell line whole exome sequencing (WES) data source (203), we screened the 
three DZNep-resistant cell lines (HT, CA-46 and DG-75) to check for alterations in AHCY. We 
identified in one of the cell lines HT, a missense point mutation in AHCY resulting in the base 
exchange A>G (table 10). Other DZNep-resistant cell lines CA-46 and DG-75 lacked this 
mutation. 
Table 10. Heterozygous mutation of the AHCY gene in HT cell line, and the predicted consequence. 
Cell line Genotype Consequence Amino acid class change (VEP 
Ensembl) 
Protein (VEP Ensembl) VEP 
(PolyPhen prediction / 
SIFT prediction) 
HT 0/1  Missense variant From hydrophobic, polar, small to 
hydrophobic, small, tiny 
ENSP00000217426.2:p.Thr84Ala Probably damaging / 
Deleterious  
(low confidence) 
VEP: Variant effect predictor; polymorphism phenotyping (PolyPhen) and sorting intolerant from tolerant (SIFT): 
Databases predicting effects of nonsynonymous / missense variants. 
Observing that the mutation is of a heterozygous genotype, we examined which allele was 
expressed in the cell. To achieve this, we designed forward and reverse primers spanning the 
region of the identified mutation Thr84 (see primer sequence in table 3). Using cDNA 
synthesized from the RNA of this cell line, we amplified this region in a PCR assay. After 
confirmation of PCR product amplification, the resultant PCR products were cleaned-up and 
Sanger sequenced to identify the expressed AHCY allele. The results of Sanger sequencing 
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showed that both the mutated as well as the normal AHCY allele are expressed in this cell line 
(figure 18). 
 
Figure 18. The mutated and wild-type AHCY alleles are expressed in HT. Red arrow shows single nucleotide 
substitution at position 84A>G on exon 3 (reference genome GRCh38.p13). ACC codes for Threonine (Thr), GCC 
codes for alanine (Ala). 
 
3.16. Analysis of publicly available genomic data sets for alterations of AHCY 
We also performed mutation analysis and copy number variation analysis of genomic data 
derived from 5 studies comprising 1295 DLBCL primary samples uploaded onto the cBio Portal 



















Blockage of cell proliferation is thought to be overarching concept of cancer therapy. This can 
be achieved by a systemic application of cytotoxic drugs (chemotherapy) which stops cellular 
division of all types of proliferating cells including cancer cells. In contrast, targeted therapy 
aims at specific blocking of (altered) driver genes known to promote cell proliferations. 
Blockage of entire cellular processes associated with tumor growth such as epigenetic 
mechanisms is a further treatment option intermediate between chemotherapy and targeted 
therapy. Epigenetic drugs are advantageous in that they induce reversible changes that 
influences gene expression without changing the nucleotide sequence that could adversely 
affect gene function. However, like many other chemotherapeutic agents, the non-specificity 
and cytotoxicity of these drugs is a pertinent limitation to their use (206). In this work, the 
molecular mechanisms of an epigenetic drug (DZNep) was studied in detail. 
4.1 DZNep induces apoptosis and inhibits proliferation in B-cell lymphoma irrespective 
of the lymphoma type, the EZH2 mutation state and the presence of MYC, BCL2 and 
BCL6 translocations 
DZNep is still in the preclinical phase of drug development, and so far, studies focusing on its 
tumor suppressive capacity has shown successful results in different cancer types (141, 143, 
156, 171, 207-210). We examined the anti-tumor effects of DZNep in B-cell lymphoma cells 
in vitro. Our results showed the strong in vitro capacity of DZNep in inducing apoptosis and 
inhibiting growth of B-cell lymphoma cell lines. The EZH2 mutation status and the presence of 
MYC, BCL2 and BCL6 translocations in the cells did not seem to matter in this respect.  
4.1.1 Many cell lines are sensitive to DZNep while some are resistant 
We demonstrated that DZNep has a strong apoptotic capacity in lymphoma cell lines. This is 
in line with findings from other studies investigating the apoptotic effect of DZNep on leukemia 
cells (210), cholangiocarcinoma cells (209), chondrosarcoma cells (141) and breast cancer cells 
(167, 211). Moreover, the concentration and time required for a drug to exert its 
pharmacological action is very essential for a rational achievement of the envisaged effect of 
that drug. We revealed that the apoptotic effects triggered by DZNep is dependent on the 
concentration of DZNep used and the duration of DZNep application (figures 4A and 4B). 
These results conform with similar concentration- and time-dependence of apoptosis reports in 
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acute myeloid leukemia (169), mantle cell lymphoma (207), non-small cell lung cancer (212), 
colon cancer (213), breast and colorectal cancer (167), and acute myeloid leukemia cells (168).  
We also showed from our IC50 results (figure 4D) that not all lymphoma cell lines are sensitive 
to DZNep. This was further confirmed by the Western blot results (figure 4E) showing cleaved 
PARP expression in two representative cell lines taken from the resistant group. The consistent 
expression of cleaved PARP in the DZNep-resistant cell lines following treatment with 
increasing DZNep concentrations signifies that these cell lines are indeed resistant to apoptosis. 
4.1.2 Sensitivity of B-cell lymphoma cell lines to DZNep does not depend on the EZH2 
mutation status, and MYC, BCL2 and BCL6 translocations 
The prognostic impact of MYC, BCL2 and BCL6 translocations in B-cell lymphomas has been 
reported (214-220), enabling patient risk assessment including a more intensive monitoring of 
the disease. We analyzed 12 B-cell lymphoma cell lines for the presence of the frequently 
reported EZH2 driver mutations (Tyr646, Ala682 and Ala692), and the presence of 
translocations involving MYC (8q24), BCL2 (18q21) and BCL6 (3q27). This was done to 
investigate the association between the lymphoma type, the EZH2 mutation situation, the MYC, 
BCL2 and BCL6 translocation profile, and the sensitivity of the lymphoma cell lines to 
apoptosis following DZNep treatment.  
Consistent with previous studies (127, 221), analysis of the lymphoma cell lines studied in this 
work revealed a higher frequency of occurrence of the EZH2 Tyr646 mutation in relation to the 
EZH2 Ala682 and EZH2 Ala692 mutation (figure 5A and table 6). Several studies focusing on 
the impact of EZH2 point mutations and overexpression in cancer have also reported this EZH2 
Tyr646 mutation (30, 31, 127, 129, 221, 222). In line with previous works (31, 129, 223), our 
data (table 6) showed that the Tyr646 mutation presents mainly in DLBCLs having BCL2 
translocations. In contrast to other direct EZH2 inhibitors (139, 146, 152), we illustrated that 
sensitivity to DZNep-mediated apoptosis or strength of apoptosis upon DZNep treatment does 
not depend on the presence of the EZH2 Tyr 646 mutation (Table 6 and figure 5C). More so, 
our findings (figure 5B and table 6) indicate a poor correlation between sensitivity to DZNep 




4.1.3 Impact of mutated and wild-type EZH2 on H3K27me3 in B-cell lymphoma cell 
lines 
It is known that mutated EZH2 drives the increased H3K27me3 in B-cell lymphoma (222-224). 
To determine if this also holds true for the lymphoma cell lines used in this work, we isolated 
total protein lysates from both EZH2-mutated and wild-type EZH2 cell lines and determined 
the level of H3K27me3 using Western blot. We demonstrated that cell lines with mutated EZH2 
exhibited increased H3K27me3 levels (figure 6), the aftermath culminating in gene silencing 
(222-226). We also revealed that apoptosis induction in DZNep-sensitive cell lines following 
DZNep treatment is associated with downregulation of EZH2 and H3K27me3 (figure 7A). This 
is also the case with chondrosarcoma cell lines (141) and breast cancer cell lines (167) treated 
with DZNep, signifying that DZNep influences both EZH2 and H3H27me3. Furthermore, even 
though there is an increase in H3K27me3 levels created by mutated EZH2, this does not limit 
the capacity of DZNep to lower the expression of this protein and cause the cells involved into 
undergo apoptosis (figure 7B).  
4.1.4 DZNep inhibits proliferation of B-cell lymphoma cell lines 
As uncontrolled proliferation remains a primary problem propelling cancer development and 
progression, we interrogated the effect of DZNep on the proliferation of B-cell lymphoma cells. 
To achieve this, we applied two methods. One was by checking the expression of genes known 
to be proliferation markers such as PCNA (227, 228) and CDK2 (229, 230). In the cell lines 
analyzed, there was a decrease in the expression of these genes following treatment of the cells 
with DZNep (figure 8A), indicating the anti-proliferative property of DZNep. However, bearing 
in mind that apoptotic and dead cells may downregulate these genes and that they were not 
excluded from the cohort of cells used for the gene expression analysis, we analyzed cell 
proliferation using flow cytometry (figure 8B). Our findings align with related reports on the 
anti-proliferative effects of DZNep in various cancer cell lines (141, 209, 212, 231) and in mice 
models (156, 169, 171, 207, 232). It is interesting to note that the anti-proliferative effects of 
DZNep was observed in all cell lines analyzed and was not dependent on the EZH2 mutation 
situation of the cells. Inhibition of proliferation by DZNep was also noted to be time-dependent 
as was observed in other cells such as erythroleukemia cells (233) and colon cancer cells (213). 
4.1.5 DZNep shows a stronger apoptotic effect in B-cell lymphoma cell lines compared to 
EPZ-6438 
Upon comparing the apoptotic capacity of DZNep and EPZ-6438 (a direct EZH2 inhibitor in 
phase II clinical trials for B-cell NHL patients (234)) in aggressive B-cell lymphoma cell lines, 
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our results illustrated that DZNep has no tendency to preferentially cause apoptosis based on 
the EZH2 mutation status of the cells (figure 9A). Our results also portrayed that DZNep is 
faster in causing apoptosis in comparison to EPZ-6438. A previous study showed that extended 
treatment with EPZ-6438 resulted in the selective killing of mutant EZH2 lymphoma cell lines 
and xenograft models (139). Based on our results (figure 9B), there was no particular difference 
in the fraction of apoptotic cells measured in the EZH2-mutated and wild-type EZH2 DZNep-
sensitive cell lines following prolonged treatment with the inhibitor. In the case of HT, the 
DZNep-resistant cell line possessing wild-type EZH2, we noticed a marked increase in the 
percentage of apoptotic cells after the third day of treatment with EPZ-6438. This indicates that 
EPZ-6438 is capable of inducing apoptosis irrespective of the EZH2 mutation status of 
lymphoma cell lines, although a longer time may be required for the apoptotic effects become 
manifest. We were curious to know whether EPZ-6438 could also invoke a robust apoptotic 
response in the DZNep-sensitive wild-type EZH2 cell line (BLUE-1) that was used for the 
generation of the DZNep-resistant clone subsequently used in this work. We treated the parent 
BLUE-1 cell line, the DZNep-resistant clone (BLUE-1R10) and its corresponding control 
(BLUE-1K10) with EPZ-6438 for up to 13 days as done in the previous experiment (figure 9B). 
In all three cell lines, there was no prominent rise in the percentage of apoptotic cells when 
treated with 10 µM of the inhibitor. This means that it is possible for a DZNep-sensitive cell 
line to be EPZ-6438-resistant. Meanwhile, the DZNep-resistant clone, although DZNep-
resistant was also EPZ-6438-resistant (figure 9C).  
4.2 Alterations of the AHCY gene could be linked with the resistance of B-cell lymphoma 
to DZNep-mediated apoptosis 
Evolution of resistance to small molecule inhibitors used in cancer therapy is still a huge 
problem leading to the failure many - initially successful - targeted therapeutics (235). As 
different mechanisms contribute to the resistance of cancer cells to therapy (178, 236, 237), we 
sought to investigate in our case, the mechanism underlying the resistance of B-cell lymphoma 
cell lines to DZNep.  
4.2.1 Characterization of the DZNep-resistant clone possessing acquired resistance to 
DZNep 
Having obtained distinct responses to apoptosis following treatment of the 12 B-cell lymphoma 
cell lines with DZNep, we focused on the DZNep-resistant group, delving into the reason 
behind this resistance by generating a DZNep-resistant clone from a DZNep-sensitive 
lymphoma cell line BLUE-1. This clone was used as a model to study the resistance mechanism 
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to DZNep, as well as to aid with the detection of biomarkers that would be predictive of the 
therapeutic benefit of EZH2 inhibition using DZNep. Similar in vitro cell line models have been 
established and used to study mechanisms of resistance to drugs in different cancer types, for 
instance in gastric cancer (238), colorectal cancer (239), colon cancer (240) and non-small cell 
lung cancer (241). Subsequent characterization of the DZNep-resistant clone revealed 
similarities to the parent cell line in many characteristics but its response to DZNep apoptotic 
pressure.  
The first step in characterizing this clone was to check if it actually derived from the parent cell 
line. Owing to the fact that we worked with several cell line clones in parallel during the 
generation of the DZNep-resistant clone, we considered that there could be a possibility for 
cross-contamination of the clone with other cell lines during the long-term cultivation. 
Moreover, we are aware that sub-clonal populations could arise in the clone due to long-term 
drug selection pressure. To confirm that the generated resistant clone represents indeed the same 
cell line derived from the parent cell line BLUE-1, we investigated the resistant clone BLUE-
1R10 (isolated after 7 months in culture). We explored the expression of cell surface markers 
CD19 and CD20 on the cell line, analyzed its STR profile and determined its clonality by 
checking the IGH gene rearrangement pattern. 
CD19 and CD20 are specific B-cell markers with a quite consistent expression in B-cell 
lymphomas (242, 243). However, in rare cases, some B-cell lymphoma types are CD19-
negative (244, 245) or CD20-negative (246, 247). BLUE-1 is one of the cell lines used in this 
work, which unlike several others, does not express the cell surface marker CD20 (see DSMZ 
data sheet with number: ACC-594). As expected, BLUE-1R10 and BLUE-1K10, just as BLUE-
1 expressed CD19 but not CD20 (figure 10A), indicating a great likelihood that the cell lines 
were not mixed up with other cell lines during the cultivation period. In addition, the identical 
IGH chain gene rearrangement profile for the three cell lines (figure 10B) also confirmed that 
both BLUE-1K10 and BLUE-1R10 originated from the same parent. Furthermore, STR 
profiling of the three cell lines confirmed that they are all BLUE-1 cell lines. 
Subsequent analysis of BLUE-1R10, BLUE-1K10 and BLUE-1 revealed slight differences in 
the karyotype (figure 10C). This underscores the point that although they originate from the 
same cell line, there are some chromosomal differences existing among them. 
Contrary to a previous study which reported that acquired drug resistance due to prolonged drug 
exposure is associated with increased doubling time in colon cancer cell lines (240), BLUE-
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1R10 showed a reduced doubling time in comparison to the parent cell line (figure 10D). We 
cannot conclude that the shorter doubling time observed in BLUE-1R10 is due to the DZNep 
treatments because, BLUE-1K10 (the corresponding control of BLUE-1R10), which did not 
receive any DZNep treatment also showed a shorter doubling time. Besides, since evolution of 
human cancer cell lines could result in a high degree of genetic heterogeneity (248), it could be 
that certain genetic changes might have occurred in the cells due to prolonged cultivation. 
Perhaps, by analyzing RNA sequencing data derived from the parent cell line (BLUE-1) in 
addition to that of the resistant clone and its control, we could be able to identify proliferation 
targets, identical to the two cell lines (BLUE-1K10 and BLUE-1R10) but different from BLUE-
1. Functional validation of these targets could give us a hint on the biological markers 
responsible for the increased proliferation rate observed in the two long-term-cultured cell lines.  
We also compared the apoptotic response of the resistant clone and its corresponding control to 
DZNep. We observed that treatment of this clone with 5 µM DZNep, a concentration 25 fold 
greater than that used to initiate treatment (during generation of the clone), the cells remained 
resistant to DZNep (figure 10E). The corresponding control displayed however, a robust 
apoptotic response following treatment with the same DZNep concentration. This shows that 
the resistance of the resistant clone to DZNep is a stable phenomenon persisting even following 
cultivation of BLUE-1R10 in a medium devoid of DZNep. 
4.2.2 Detection of biomarkers determining DZNep resistance 
Since we already know that chromosomal disparities exist among the three cell lines, we went 
further to identify DNA structural variants that cause a loss or gain of chromosomal segments 
by performing the genome-wide OncoScan copy number variation (CNV) assay. We disclosed 
3 aberrations exclusive to BLUE-1R10, 3 anomalies present only in BLUE-1 and 4 aberrations 
existing only in both BLUE-1 and BLUE-1R10 (table 7). This reflects the level of genomic 
variation and chromosomal instability that could occur following long-term culture of cell lines 
in vitro under different conditions. 
Although the OncoScan assay is a fast, easy and highly sensitive method for the detection of 
genome-wide copy number alterations (249), data output can be limited by inadequate number 
of probes for certain genes/genomic regions (250). Whole exome sequencing (WES) approach 
provides a better resolution and higher accuracy for the interrogation of cancer-related genes 
(250), especially for detecting small copy number changes in regions of low probe coverage 
with the former assay. 
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For this reason, we subjected the resistant clone BLUE-1R10 and its control BLUE-1K10 to 
WES. Upon analysis of the sequencing data, we identified copy number alterations in several 
targets in the resistant clone in relation to its control. These include copy number variations on 
chromosome 6 (SNHG5, SMIM11P1, HTR1E and CGA genes) and on chromosome 20 (AHCY 
gene, extending until the proximal part of the ITCH gene) (figure 11B). SNHG5 codes a long 
non-coding RNA, and has been shown to play a role in the progression of bladder cancer (251). 
While SMIM11P1 is a pseudogene and encodes no protein, HTR1E codes the serotonin receptor 
1E (252). CGA codes the alpha subunit of the four human glycoprotein hormones; luteinizing 
hormone, chorionic gonadotropin, thyroid-stimulating hormone and follicle stimulating 
hormone, whereas, the ITCH gene encodes a member of the HECT domain E3 ubiquitin ligases 
that target particular proteins for degradation by the lysosome (252). AHCY gene encodes S-
adenosylhomocysteine hydrolase, which catalyzes the reversible hydrolysis of SAH to 
adenosine and homocysteine (161, 162), thereby controlling the concentration of SAH 
necessary for methylation reactions within the cell (252). From the list of genes with copy 
number variation, AHCY seemed most promising for further investigation as to the reason 
behind the resistance of the clone to DZNep, as DZNep directly inhibits AHCY. 
4.2.3 Validation of AHCY copy number variation in the DZNep-resistant clone, other B-
cell lymphoma cell lines and primary lymphoma samples 
To validate the AHCY copy number variation observed in the DZNep-resistant clone, we used 
a simple, but specific and reproducible method - the TaqMan Copy Number Assay - to detect 
copy number changes. We analyzed genomic DNA from all 12 (DZNep-sensitive and DZNep-
resistant) B-cell lymphoma cell lines, including the resistant clone. We detected a remarkable 
gain in the AHCY copy number in BLUE-1R10, and a further increase in the number in BLUE-
1R12 (figure 12A). This progressive gain in the number of copies of AHCY was observed from 
BLUE-1R6, obtained on the fifth month of treatment of BLUE-1 with DZNep (figures 12B and 
12C). This implies that the presence of DZNep is not necessary for the gain in AHCY copy 
number in the clone once this gain is established. Other lymphoma cell lines analyzed did not 
show this profound AHCY copy number gain. 
From the results of the CNV assay performed using the DNA methylation data from BLUE-1, 
BLUE-1K10 and BLUE-1R10, we also confirmed the AHCY copy number gain in the resistant 
clone (figure 12D). Furthermore, manually evaluating the OncoScan CNV data, laying 
emphasis on the AHCY locus on chromosome 20, we detected 8 probes with a high log2 ratio 
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in BLUE-1R10, which was absent from BLUE-1K10 and BLUE-1 (figure 12E). This was 
filtered out due to the stringent criteria for calling an event a CNA (see section 2.13). 
Using chromosome 20-specific DNA probes for AHCY, we also validated the AHCY copy 
number gain in the resistant clone at the chromosomal level. This was performed using FISH, 
a powerful technique used for the detection of chromosomal anomalies in tissues (253, 254). 
Our FISH results confirmed this AHCY copy number gain (figure 12F) observed in cells of the 
resistant clone (BLUE-1R10 and BLUE-1R12) when compared with their corresponding 
controls (BLUE-1K10 and BLUE-1K12) respectively. This further affirms that the AHCY gain 
in the clone is a continuous process.  
In cases where the target of a drug is an enzyme, modifications such as changes in the 
expression levels of the drug target can lead to resistance to the drug (178, 255). We therefore, 
investigated the expression of AHCY at both the transcriptional and protein level. We showed 
that AHCY is overexpressed in BLUE-1R10 and BLUE-1R12. Other B-cell lymphoma cell 
lines examined did not show a comparable increase in the expression of AHCY in relation to 
the DZNep-resistant clone (figures 12G, 12H and 12I). The absence of overexpressed AHCY 
in other B-cell lymphoma cell lines is an indicator that this mechanism of resistance is unique 
to the resistant clone, which possesses an acquired resistance to DZNep. Other DZNep resistant 
cell lines with an intrinsic resistance to DZNep may have other underlying mechanisms 
independent of AHCY overexpression.  
In comparison with cervical cancer (256), colon cancer (257) and colorectal cancer (258) where 
copy number gains of AHCY has been associated with disease pathogenesis, not much is known 
about the part gains of AHCY play in aggressive B-cell lymphoma progression. If copy number 
gains of the AHCY gene were a frequent occurrence in lymphomas, then the translation of 
DZNep into clinical application in patients with this alteration might be accompanied with 
resistance to the drug. We examined the AHCY CNV profile for 11 lymphoma patient samples 
to check if this alteration could be detected. None of the samples analyzed displayed gains of 
AHCY however, one out of the 11 samples showed a deletion of one copy of the AHCY gene 
(figure 12K). We are uncertain about the effects of reduced AHCY copy number in lymphoma 
cells and what functional impact this may create, or if alternative / rescue mechanisms may set 
in to enable proper functioning of the cells.  
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4.2.4 DZNep decreases AHCY expression 
In addition to the fact that DZNep directly inhibits AHCY (159, 259), we depict that DZNep 
also decreases the expression of AHCY in B-cell lymphoma cell lines. Even in the DZNep-
resistant clone with overexpressed AHCY, there was a mild decrease in the AHCY expression 
following DZNep treatment. This effect however, was still ineffective in lowering the AHCY 
levels to that obtainable in other basic B-cell lymphoma cells lines (figure 13). The slight 
reduction of AHCY expression in the clone could thus, result in little to no effect of DZNep in 
potentiating the downstream effects of EZH2 inhibition and apoptosis induction in this cell line. 
One may argue that the AHCY downregulation observed may be due to dead or apoptotic cells 
precipitated by DZNep treatment. However, we also noticed that in the DZNep-resistant cell 
lines BLUE-1R10 and HT, just like in the DZNep-sensitive cell lines BL-41, BLUE-1 and 
BLUE-1K10, there was also a decrease in AHCY expression following DZNep treatment. 
4.2.5 DZNep influences the methylation process by mediating effects on intermediates of 
methionine  
The importance of metabolomics in studying disease mechanisms and in biomarker 
identification in cannot be overemphasized (260-263). To this end, we studied the dynamics of 
select intermediates of methionine metabolism including SAH, adenine and adenosine in the 
resistant clone (BLUE-1R10 and BLUE-1R12), their controls (BLUE-1K10 and BLUE-1K12 
respectively) and the parent cell line (BLUE-1). The comparable pattern in which the mentioned 
intermediates were distributed in BLUE-1, BLUE-1K10 and BLUE-1K12 (figure 14) indicates 
that even after long-term cultivation of the cell lines, the manner in which the respective 
intermediates disseminated within the cell was not considerably altered. Upon treatment of the 
resistant clone (BLUE-1R10) with DZNep however, we clearly observed an increase in the 
quantity of SAH. This signifies that DZNep really inhibits AHCY resulting in the buildup of 
SAH levels (159), with EZH2 inhibition being one consequence of this SAH elevation (159, 
167, 210). Nevertheless, this AHCY inhibition is not sufficient to make the resistant clone 
sensitive to the apoptotic effects of DZNep. In the resistant clone without DZNep pressure 
however (BLUE-1R12), there was a clear rise in both adenine and adenosine levels in 
comparison with its control BLUE-1K12. This surge could be because, due to the increased 
AHCY expression in this clone, there is an increased AHCY-mediated hydrolysis of SAH, 
favoring the forward reaction that results in adenosine production.  
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4.2.6 Differentially methylated targets involved in DZNep-mediated apoptosis 
DNA methylation patterns can provide important information concerning the prognosis of a 
disease and response to drugs (264, 265). We analyzed the global DNA methylation profile of 
the resistant clone and its control with and without DZNep pressure, as well as that of the parent 
BLUE-1 cell line. We observed that the ELISA-based method we initially used for the 
colorimetric determination of the global DNA methylation level in the cell lines was not 
reproducible (figure 15A). We therefore used the MethylationEPIC BeadChip microarray, 
which provides high reproducibility across replicate samples (266). The hierarchical clustering 
and PCA created using the methylation data of the cell lines showed high similarity between 
replicates (figures 15B and 15C respectively). This gave more assurance that samples were not 
mixed-up, and further confirmed the reproducibility of this adopted method. Even with the 
identical clustering of replicate samples, the parent cell line and the control for the resistant 
clone clustered more together. In the presence of DZNep however, the control for the resistant 
clone clustered more with the resistant clone. This shows that in presence of DZNep, there is a 
tendency for the methylation pattern to progress towards the direction of the DZNep-resistant 
phenotype. That notwithstanding, even with the intra-group differences, the cell lines clustered 
more with the inclusion of the primary tumor methylation data. This shows that although there 
are differences in the methylation pattern of the resistant clone as well as its control, the parent 
cell line and DZNep treated cells, these changes are rather subtle. Upon comparison of the cell 
line methylation data with methylation data from primary lymphoma and plasmacytoma 
samples, we observed from the clustering, more similarity between the primary tumor samples 
irrespective of the type of primary samples (figure 15B). This suggests that irrespective of the 
type of primary tumor type, DNA methylation patterns of primary tumor samples are somewhat 
distinct from that of cell lines. 
Further analysis of differentially methylated genes yielded several targets whose methylation 
patterns differed between the various cell lines analyzed (BLUE-1K10 versus BLUE-1R10, 
DZNep-sensitive versus DZNep-resistant, and BLUE-1K10 versus BLUE-1K10 plus DZNep) 
(figures 15D and 15E). Of particular interest, we find no differentially methylated target genes 
between the resistant clone in presence and absence of DZNep based on the used criteria for 
defining differentially methylated probes (figure 15E). This is an indicator that the resistant 
clone is indeed resistant to DZNep. Differently methylated genes were however, detected in the 
clone’s control BLUE-1K10 when comparing DZNep-treated and -untreated conditions. The 
differentially methylated genes involved in the apoptosis signaling pathway were explored 
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between groups 1 (BLUE-1K10 versus BLUE-1R10), 2 (DZNep-resistant versus DZNep-
sensitive cell lines) and 3 (BLUE-1K10 in presence versus absence of DZNep pressure). The 
resulting gene list (table 8) highlights the group of differentially methylated target genes whose 
methylation states may likely affect these cell lines’ response to apoptosis by DZNep. Already, 
particular methylation states of several of these targets have been associated with different types 
of cancers, for example in hepatocellular carcinoma and papillary renal cell carcinoma, 
hypermethylation of the PRKCH gene has been reported, while in prostate carcinoma, 
hypomethylation of AKT3 has been recorded (267). The effect of the different DNA methylation 
states on the cell lines’ response to apoptosis would depend on the type and location of the 
methylation mark on these genes.  
4.2.7 Validation of the functional role of AHCY copy number gain 
To annotate the functional impact of AHCY overexpression, we worked on knocking down 
AHCY in the resistant clone BLUE-1R10. This was performed to check if this clone would 
regain sensitivity to DZNep. Upon several trials (explained in section 3.13), we discovered that 
due to the overexpressed AHCY in the resistant clone, we were unable to achieve an efficient 
AHCY knockdown (at the protein level) to levels lower than that obtainable in a basic BLUE-
1 cell line. Perhaps, if we had used the resistant clone isolated at an earlier time point during its 
evolution (for instance, BLUE-1R6), we might have been able to knock down AHCY to much 
lower levels that would allow for the functional investigation of the effect of AHCY copy 
number gain in the cells.  
We also attempted to overexpress AHCY in three DZNep-sensitive B-cell lymphoma cell lines 
and one DZNep-sensitive osteosarcoma cell line (U-2-OS). After transfecting them using the 
same method (lipofection), AHCY was overexpressed only in U-2-OS (figure 17A). This is not 
so surprising because lymphoma cells are one of the known cell types that are difficult to 
transfect (268-270). Results of downstream analysis of the AHCY-overexpressed U-2-OS cell 
line and its untransfected control suggests that AHCY overexpression tends to be associated 
with resistance of the cells to apoptosis mediated by DZNep (figure 17B). This can however 
not be completely justified since we do not have the data from the negative control-transfected 
U-2-OS cells. It would also be interesting to test if overexpression of AHCY in the DZNep-
sensitive lymphoma cell lines by other gene delivery options such as the use of viral vectors 
would yield a successful outcome. 
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4.2.8 AHCY alterations are not frequent but can occur in B-cell lymphoma 
We checked the WES data of DZNep-resistant cell lines HT, CA-46 and DG-75 (203) for 
genomic alterations of AHCY, and detected an AHCY point mutation predicted to have a 
probably damaging consequence in the cell line HT (table 10). Both the mutated and wild-type 
alleles were also expressed in this cell line at the mRNA level (figure 18). Since this was the 
case, it translates that both the mutated and the normal AHCY protein would be present in the 
cell. We presume that this mutation, although not located in the AHCY binding site, may play 
a role in the resistance of this cell line to DZNep. The impact of this mutation, which still needs 
to be verified, would depend on the ratio of the protein amounts translated from the mutated 
and wild-type AHCY mRNAs, as well as on the effects of post-translational modifications on 
both proteins.  
The lack of AHCY alterations in the cases of DLBCL primary samples analyzed from the 
publicly available database (204, 205) shows that AHCY alterations are infrequent in DLBCLs. 
However, based on the cancer type, AHCY mutations and amplifications in solid tumors can be 















With the increasing need for new and better ways to tackle cancers, there is a high demand for 
novel drugs with a good therapeutic efficacy and limited side effects. Moreover, resistance to 
cancer chemotherapeutics could be a problem during drug usage therefore, discerning tumor 
resistance mechanisms and determining predictive biomarkers that could aid in preventing this 
issue from emerging beforehand is essential.  
In this work, we confirmed the anti-tumor characteristics of DZNep; highlighting its strong 
apoptotic and anti-proliferative capacity in aggressive B-cell lymphoma cell lines. These tumor-
antagonistic effects were mediated independent of the presence of the EZH2 driver mutation 
(Tyr646), as well as MYC, BCL2 and BCL6 translocations. Furthermore, we demonstrated that 
the presence of EZH2 gain-of-function mutations did not reduce the capacity of DZNep to 
promote apoptosis in these B-cell lymphoma cell lines.  
We also showed that alterations of the AHCY gene are a potential mechanism through which 
resistance to DZNep-mediated apoptosis could occur in aggressive B-cell lymphomas. These 
alterations include, but are not limited to copy number variations and mutations of the AHCY 
gene. Furthermore, acquired resistance mechanisms to DZNep-mediated apoptosis in 
aggressive B-cell lymphomas may differ from mechanisms of intrinsic resistance which 
themselves, may vary due to the great level of genetic heterogeneity in cells. Despite the rarity 
of AHCY anomalies in primary lymphomas, screening for alterations of AHCY or the associated 
pathway in patients may still be necessary before the use of DZNep. Whether DZNep could be 
a more powerful epigenetic drug against DZNep-resistant B-cell lymphoma cells when 
combined with other (epigenetic) drugs still needs to be investigated. 
Lastly, despite the challenges involved with in vitro studies, evolution studies with cell lines 
still present a promising method for studying resistance mechanisms to DZNep. This study 
provides better understanding on the molecular mechanism of resistance to DZNep and 
advocates AHCY as a promising prognostic biomarker for EZH2-based therapeutic 
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5-mC 5-methylcytocine 
6-FAM 6-carboxyfluorescein 
ABC Activated B‐cell 
AEBP2 Adipocyte enhancer-binding protein 2 
AHCY S-adenosylhomocysteine hydrolase 
Ann V Annexin V 
B2M Beta 2 microglobulin 
BCL B-cell lymphoma  
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CD Cluster of differentiation 
CDK2 Cyclin-dependent kinase 2 
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CNN-LOH Copy number neutral loss of heterozygosity 
CNV Copy number variation 
DLBCL Diffuse large B-cell lymphoma 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DSMZ German collection of microorganisms and cell cultures 
DZNep 3-Deazaneplanocin-A 
EED Embryonic ectoderm development 
ELISA Enzyme-linked immunosorbent assay 
esiRNA Endoribonuclease-prepared small interfering RNA 
EZH1 Enhancer of zeste homolog 1 
EZH2 Enhancer of zeste homolog 2 
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FITC Fluorescein isothiocyanate 
FR Framework 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GCB Germinal center B‐cell 
GFP Green fluorescent protein 
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H3K27me3 Lysine 27 tri-methylation on histone H3 
HIV Human immunodeficiency virus 
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IC50 Inhibitory concentration 50 
IGH Immunoglobulin heavy chain 
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JARID2 Jumonji and AT-rich interaction domain containing 2 
Me Methyl 
NCBI National Center for Biotechnology Information 
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NFkB Nuclear factor kappa-light-chain-enhancer of activated B cells 
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PCNA Proliferating cell nuclear antigen 
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PGPs Polycomb group proteins 
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PRC1 Polycomb repressive complex 1 
PRC2 Polycomb repressive complex 2 
R-CHOP Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone 
RbAp46 Retinoblastoma-binding protein p46 
RNA Ribonucleic acid 
RQ Relative mRNA quantification 
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RT-PCR Reverse transcriptase polymerase chain reaction 
SAH S-adenosyl-L-homocysteine 
SAM S-adenosylmethionine 
SD Standard deviation 
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SET Suppressor of variegation, Enhancer-of-zeste and Trithorax 
SIFT Sorting intolerant from tolerant 
STR Short tandem repeat 
SUZ12 Suppressor of Zeste 12 
TCL T-cell lymphoma  
VEP Variant effect predictor 
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